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(A)PC (active) protein C 
α2-AP a2-anti plasmin 
α2-MG a2-macroglobulin 
ABCs ATP-binding cassette transporters 
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AT antithrombin III 
bFGF basic fibroblast growth factor 
BrdU 5-bromo-2-deoxyuridine 
BSA bovine serum albumin 
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ECL enhanced chemiluminescence 
EDTA Ethylenediaminetetraacetic acid 
ELISA enzyme linked immunosorbant assay 
EPCR endothelial protein C receptor 
ERK extracellular activated kinase 
FCS fetal calf serum 
FII(a) (active) factor II 
FITC fluoroscein isothiocyanate 
FIX(a) (active) factor IX 
FPLC fast performance liquid chromatography 
FSAP factor VII activating protease 
FV(a) (active) factor V 
FVII(a) (active) factor VII 
FVIII(a) (active) factor VIII 
FX(a) (active) factor X 
FXI(a) (active) factor XI 
FXII(a) (active) factor XII 
FXIII(a) (active) factor XIII 
Gpi glycosylphosphatidylinositol 
GpIbα glycoprotein Ibα 
Gp IV Glycoprotein IV 
HABP-2 hyaluronic acid binding protein-2 
HGF-A hepatocyte growth factor activator 
HRP horseradish peroxidase 
HUVEC human umbilical vein endothelial cells 
IC50 inhibitor concentration to inhibit 50 % 
ICAM-1 intracellular cellular sdhesion molecule-1 
IMDM iscov's modified medium 
kDa kilo dalton 
KIU kallikrein inhibiting units 
KM Michaelis-Menten constant 
LDL low-density lipoprotein 
LDLR LDL receptor 
LMW low molecular weight 
LPS lipopolysaccharide 
LRP LDL-receptor related protein 
mAb monoclonal antibody 
MAPK mitogen activated protein kinase 
IV 
 
MCP-1 macrophage stimulating protein 
M-CSF macrophage colony stimulating factor 
MEF mouse embryonic fibroblasts 
MI / II Marburg I / II 
MMP matrix metalloproteinase 
MW molecular weight 
OD optical density 
p(dI:dC) polydeoxyinosinic-polydeoxycytidylic acid 
p(I:C) polyinosinic-polycytidylic acid 
pAb polyclonal antibody 
PAI-1 /-2 plasminogen activator inhibitor-1 /-2 
PAR protease activated receptor 
PARP poly [ADP-ribose] polymerase 1 
PDGF platelet-derived growth factor 
PDGFR PDGF receptor 
PHBP plasma hyaluronan binding protein 
PHBSP plasma hyaluronan binding serine protease 
PI3K phosphoinositol 3 kinase 
PN-1 protease nexin-1 
PPACK D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone 
PVDF polyvinylidene fluoride 
RAP receptor associated protein 
RT room temperature 
S-2288 H-D-isoleucyl-L-prolyl-L-arginine-p-nitroanilinedihydro-chloride 
S-2444 L-pyroglutamyl-glycyl-L-arginine-p-nitroanilinedihydro-chloride 
sc single chain 
ScRs scavenger receptors 
SD standard deviation 
SDS sodium dodecyl sulfate 
SEM standard error of the mean 
SERPIN serine protease inhibitor 
SNP single nucleotide polymorphism 
TAFI thrombin activated fibrinolysis inhibitor 
TBE tris borate EDTA 
TBS tris buffered saline 
TBS-T TBS tween20 
tc two chain 
TF tissue factor 
TFPI tissue factor pathway inhibitor 
TLRs toll-like receptors 
TM thrombomodulin 
TMB 3.3’, 5.5’-tetramethylbenzidine 
tPA tissue type plasminogen activator 
UH unfractionated heparin 
uPA urokinase 
uPAR uPA receptor 
v/v volume per volume 
VCAM-1 vascular cell adhesion molecule 
VLDL very low-density lipoprotein 
VLDLR VLDL receptor 
vmax maxima velocity 
VSMC vascular smooth muscle cells 
VWF von Willebrand factor 
w/v weight per volume 
WB Western blot 
WT wild type 
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3. Introduction 
 The blood circulation is required for the transport and the supply of organs with 
metabolites, vitamins, hormones and for nutrition. The gas-exchange of oxygen and 
carbon dioxide, and the maintenance of blood- and body-pressure represent other 
features of the circulation. Leakage or obstruction of the circulation leads to severe 
pathological complications. In order to preserve the functionality of the circulation, 
evolution has developed mechanisms that circumvent extensive liquid-loss and 
reconstitute the vasculature. These homeostatic mechanisms are characterized as 
hemostasis, fibrinolysis, vascular wall remodeling and wound healing. 
 
 
3.1 Hemostasis 
Numerous proteases control the activation, regulation and coordination of 
hemostasis. These mechanisms are subject to tight control. Proteins involved in the 
coagulation process exhibit a high specificity for their substrates, cofactors and 
assembly of protein-protein complexes 1. Damaged or activated cells, platelets and 
endothelial cells serve as templates for these complex reactions. Blood coagulation on 
specified cell surfaces prevents the spread of coagulation throughout the whole vascular 
system 2. Genetic or physiological defects in these systems can lead to thromboembolic 
diseases or hemorrhagic disorders. These life-threatening circumstances indicate the 
importance of a functioning blood-coagulation system 3. 
Hemostasis can be classified into two pathways, the intrinsic or contact factor 
pathway and the extrinsic or tissue factor pathway. The key protease of the blood 
coagulation system is pro-thrombin (factor II, FII). The activation of pro-thrombin 
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generates active thrombin (FIIa), which fulfills its very important task in the cleavage 
of fibrinogen 3. 
To maintain circulation, hemostasis has to respond rapidly to vessel injury and 
prevent excessive blood loss. Subsequent to a disruption of the vascular endothelium, 
extravascular collagen or tissue factor become exposed to blood components. Vascular 
smooth muscle cells (VSMC), pericytes and adventitial fibroblasts constitutively 
express tissue factor (TF). When TF becomes complexed with FVII/FVIIa coagulation 
is initiated 4. Deficiencies in TF result in severe complications, e.g., mice lacking TF 
die during embryonic development, due to vascular and hemostatic defects 5, 6. No 
humans with a deficiency in TF have yet been identified 4. 
Platelets bound to the injured vessel wall via collagen/glycoprotein (Gp) IV 7 or 
von Willebrand factor (VWF)/GpIbα serve as a negatively charged surface for 
proteases of the coagulation cascade and ensure that the process of clot-formation is 
confined to the damaged site of the vessel wall 3. 
Categorizing hemostasis into different phases, three stages can be distinguished. 
In the initiation phase, TF/FVIIa complexes are formed and initial amounts of activated 
factor IX (FIXa) and factor X (FXa) are generated. FXa in turn associates with its 
cofactor factor Va (FVa) and forms a complex on a negatively charged phospholipid 
membrane. This assembly results in the so-called prothombinase complex. This 
complex activates FII to FIIa in the presence of Ca2+. This initial phase is followed by 
the amplification phase, where the basis is laid for the generation of large amounts of 
thrombin. Activated thrombin activates FV, factor VIII (FVIII) and small amounts of 
factor XI (FXI) on the surface of activated platelets 2. 
The amplification phase is followed by the propagation phase. FIXa binds to 
activated FVIII (FVIIIa) on the platelet surface. This complex is called the tenase 
complex. Subsequently, the tenase complex catalyzes the conversion of FX to FXa in 
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the presence of Ca2+. In situations of severe hemostatic challenge, additional amounts 
of FIXa are supplied by active FXI (FXIa) 3. 
FX activation is restricted to cell surfaces, since it is rapidly inactivated by 
tissue factor pathway inhibitor (TFPI) or antithrombin III (AT) in the fluid phase. These 
inhibitors regulate and restrict the activity of FXa to the cell surfaces where it is 
generated 2. Formation of the tenase complex on the surface of platelets, in addition to 
the TF/FVIIa complex located on cells of the damaged vessel wall, represents another 
more efficient site of FXa generation. Assembly of the tenase complex is accompanied 
by dissociation of FVIII/VWF complexes, thereby permitting additional platelet 
aggregation 1, 2. Generation of the tenase complex accelerates the formation of the 
prothrombinase complex, which produces sufficient amounts of FIIa to cleave abundant 
amounts of fibrinogen to fibrin in forming the fibrin clot. 
Under normal physiological circumstances the generation of thrombin is located 
and restricted to the surface of platelets, as illustrated by the tenase and prothrombinase 
complexes 3. Due to their importance, these two complexes are putative targets for 
therapeutical strategies to inhibit blood coagulation 1. 
To stabilize the fibrin clot, FIIa activates factor XIII (FXIII) to active FXIII 
(FXIIIa). Fibrin serves as a cofactor for FIIa-dependent activation of FXIII. When FIIa 
cleaves fibrinogen it remains bound to the produced fibrin peptides, thereby enabling it 
to activate FXIII more efficiently. Additionally, this ensures the generation of FXIIIa at 
the site where it is needed 8. FXIIIa stabilizes the fibrin clot by covalently cross-linking 
fibrin 3. FIIa remains active and promotes FXIIIa-dependent fibrin cross-linkage until 
the complete platelet clot consists of stabilized fibrin. 
The propagation phase is followed by an intrinsic anticoagulation phase, even 
though the mechanisms characterizing the termination are active throughout the process 
of blood coagulation 2. The main components of the termination phase are protein C 
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(PC), protein S and thrombomodulin (TM). PC becomes activated by FIIa and is 
converted to active PC (APC). PC activation is promoted when FIIa is bound to TM. Its 
receptor, the endothelial PC receptor (EPCR), functions as a cofactor for FIIa-
dependent PC activation. When TM is located on an endothelial cell membrane together 
with EPCR, then the activation of PC is further accelerated 9. APC, together with its 
cofactor protein S, proteolytically inactivates FVa (prothrombinase complex) and 
FVIIIa (tenase complex). This process exhibits an even higher efficiency if FVa is 
located on an endothelial cell membrane rather than on platelets 10. Apart from the 
activation of PC, the FIIa/TM complex also activates TFPI, which in turn can rapidly 
inhibit other proteases. On intact endothelial cell membranes, the presence of TM, TFPI 
and AT bound to heparan sulfate restricts the coagulatory processes to the sites of 
vessel injury2. 
AT-dependent inhibition of FIIa is inefficient without cofactors, such as, heparin 
or heparan sulfate. Both, FIIa and AT bind to these cofactors, which serve as a 
template. FIIa recognizes AT as a substrate, but is trapped by AT during the proteolysis 
reaction 3. Another inhibitor which uses a similar, but more complex mechanism, for 
the inhibition of FIIa is heparin cofactor II. As in the case of AT, glycosaminoglycans 
accelerate the efficiency of FIIa inhibition by heparin cofactor II through template-
dependent effects. Additionally, a highly acidic part of heparin cofactor II is released 
during the inhibition process, which binds FIIa at another site, thereby changing FIIa’s 
conformation 11. However, the contribution of heparin cofactor II in normal hemostasis 
has been suggested to be only secondary 3. The FIIa-inhibitor complexes generated 
during hemostasis are cleared from the circulation by receptor-mediated endocytosis 12. 
Whether proteases of the contact factor pathway (or plasma kallikrein/kinin 
system) belong to hemostasis has not been elucidated so far. Bradykinin is 
constitutively released during the cleavage of pre-kallikrein and is important for the 
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maintenance of the vascular homeostasis 13. The contribution of FXIIa to hemostasis is 
not clear. FXII becomes activated by negatively charged surfaces, such as, dextran 
sulfate, nucleic acids 14 or polyphosphate released by activated platelets 15. At the site of 
a developing thrombus, FXII may become activated to generate greater amounts of 
FXIa, thus propagating FIIa-formation 13. A FXII polymorphism exhibiting reduced 
proteolytic activity is associated with an increased risk of thrombosis, which might be 
potentially explained by an FXIIa-dependent reduced fibrinolytic activity. Controversial 
observations in FXII-deficient mice have revealed reduced thrombus size, which 
suggests a role of FXII in the development of the thrombus 13. 
Proteases of the coagulation cascade also contribute to signaling events, such as, 
the activation of protease-activated receptors (PARs). Related to hemostatic progression 
and pro-inflammatory responses, PAR-1 or PAR-2 become activated by FIIa or FXa, 
respectively 9. Not only are pro-coagulatory enzymes involved in cellular signaling, but 
also proteins that contribute to the termination of blood coagulation. APC is able to 
counteract systemic inflammation, such as in cases of sepsis, via signaling through 
PARs involving EPCR as a co-receptor 9. 
Recent reports provide evidence for the existence of intravascular TF. 
Leukocytes, platelets, cell-derived microparticels and even endothelial cells, if they 
become exposed to LPS, express TF 4. The contribution of intravascular TF to 
hemostasis and thrombosis has to be elucidated and may present new targets for 
antithrombotic therapies 4. 
Highly specific mechanisms for protein activation and subsequent inhibition are 
hallmarks of hemostasis. The assembly of protein complexes, the cofactor-dependent 
changes in substrate specificity and the cofactor-directed inhibition highlight important 
features of blood coagulation. To sum up, blood coagulation is an extremely tightly 
regulated system. 
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3.2 Fibrinolysis 
 The dissolution the formed clot is denoted by fibrinolysis. The main components 
of this mechanism are plasminogen and the plasminogen activators, namely, tissue-type 
plasminogen activator (tPA) and urokinase (uPA). The zymogen plasminogen is 
cleaved by tPA or uPA to active plasmin, which in turn degrades fibrin. Also important 
in this process are the plasminogen-activator inhibitors (PAI)-1 and -2 that inhibit the 
tPA and uPA-dependent generation of plasmin 16. Serine protease inhibitors (SERPINs) 
are present at high concentration in plasma. Proteins, such as, α2-antiplasmin (α2-AP), 
α2-macroglobulin (α2-MG) and thrombin-activated fibrinolysis inhibitor (TAFI) inhibit 
plasmin-dependent degradation of fibrin using different mechanisms 16. 
 Both plasminogen and tPA bind fibrin, which accelerates the generation of 
plasmin. Other substances, such as, collagen IV, thrombospondin and cell membrane 
components can serve as cofactors for tPA-dependent plasminogen activation as well, 
but with lower capability than fibrin 16. When plasminogen becomes activated a two-
chain conformation is formed, with kringle domains in the N-terminal heavy chain and 
the trypsin-like, serine protease domain in the C-terminal light chain. These kringle 
domains are vital in plasminogen as well as in plasmin for their interaction with 
substrates, inhibitors and cell membranes. Interaction with these substances is necessary 
for plasminogen activation, localization and the regulation of plasmin activity.
 Endothelial cells synthesize and secrete tPA in a single-chain conformation. 
Already in this conformation, tPA is a potent activator of plasminogen. The binding of 
tPA with fibrin is guided by one of its kringle domains and the finger-like domain 
(similar to that of fibronectin), both located at the N-terminal part of tPA. Processing to 
the two-chain conformation of tPA, by plasmin, kallikrein or FXa, increases its activity 
towards synthetic chromogenic substrates and plasminogen in the absence of fibrin. 
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Affinity towards its inhibitors is also higher for two-chain tPA 16, 17. The inhibition of 
tPA by PAI-1 involves the catalytic domain of tPA, as well as a site located in one of its 
kringle domains. TPA-PAI-1 complexes exhibit a binding capacity to fibrin, which 
increases the inhibitory effect of PAI-1 by blocking of putative binding sites on the 
fibrin clot for free tPA 18. 
 In contrast to tPA, uPA exhibits no specific binding affinity for fibrin. The uPA 
concentration in plasma is lower compared to tPA, but nevertheless, an intravenous 
infusion of single-chain (sc)-uPA increases the lysis of thrombi in a plasminogen-
independent fashion 16. Sc-uPA is cleaved by plasmin, kallikrein, stromelysine-1 or FIIa 
resulting in different outcomes concerning uPA activity. Plasmin or kallikrein release a 
two-chain uPA variant that exhibits full proteolytic activity, whereas FIIa forms a 
variant that is not able to cleave plasminogen in vitro, but can induce thrombolysis in 
vivo. This FIIa-generated uPA-variant can be further processed by plasmin to generate 
active uPA 16. A unique feature among components of the fibrinolysis system is the 
existence of a specialized cell-surface receptor for uPA, the uPA receptor (uPAR). This 
receptor is a cystein-rich glycoprotein that is expressed by many cell types. The uPAR 
is covalently linked to the cell surface via a glycosylphosphatidylinositol (GPI)-anchor. 
The epidermal growth factor-like (EGF) domain of uPA is important for its interaction 
with the N-terminal region of uPAR. This interaction appears to be specific, since other 
proteins containing EGF domains lack an interaction with uPAR 16. The interaction of 
uPA with uPAR has been suggested to regulate pericellular proteolysis by activating 
plasminogen and initiating intracellular signaling cascades. These processes are 
important for cellular development 16 and wound-healing 19. Whereas uPA seems to be 
more important for cell surface-located plasminogen activation, tPA, with its fibrin-
binding feature, is suggested to be important for the lysis of fibrin clots in the 
circulation 20. 
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 PAI-1 is expressed in almost all cell types including endothelial cells, 
hepatocytes and adipocytes 19, and inhibits single-chain and two-chain tPA; whereas 
PAI-2 is expressed by monocytes, macrophages and by the placenta 16, and only inhibits 
two-chain tPA. Platelet α-granules contain large amounts of PAI-1, which is released 
upon platelet stimulation and results in a local increase of PAI-1 at sites of thrombus 
formation. Thereby, PAI-1 increases the resistance of the fibrin matrix to proteolytic 
degradation 21. PAI-1 in plasma is spontaneously converted from its active 
conformation into latent PAI-1. The active conformation of PAI-1 is stabilized by 
specific binding to vitronectin 16, again increasing local capability to increase thrombus 
stability. 
 Inhibitors of plasmin, such as α2-AP, TAFI and α2-MG play important roles in 
regulating the fibrinolytic process. α2-AP binds to fibrin and is covalently linked to the 
fibrin clot by FXIIIa. The efficient inhibition of plasmin by α2-AP is dependent on its 
binding to fibrin. The generated plasmin which cleaves fibrin in the first instance, 
thereby creating new high-affinity binding sites for plasminogen and tPA, is directly 
inhibited by α2-AP 22. Inhibition of plasmin by α2-MG, in comparison to inhibition by 
α2-AP, follows a lower rate and does not lead to complete inactivation of plasmin. 
However, α2-MG remains an important regulator of plasmin activity because of its very 
high plasma-level as compared to other inhibitors (α2-MG = 2.5 mg/ml; α2-AP = 0.07 
mg/ml) 16. 
FIIa or plasmin can activate TAFI. The efficiency of TAFI activation by FIIa 
increases when FIIa is bound to TM, which usually promotes anti-thrombotic activities 
9. The activation rate of TAFI by plasmin is increased when glycosaminoglycans, such 
as unfractionated heparin are present 16. TAFI inhibits fibrinolysis by a cleavage of C-
terminal Lys- or Arg-residues, those generated during the initial cleavage of fibrin by 
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plasmin and forming the new high-affinity binding sites for tPA and plasminogen. 
TAFI-related cleavage of fibrin, therefore, prevents the additional binding of 
plasminogen and tPA, preserving fibrin stability 23. 
 Members of the fibrinolysis system are crucial in the development of 
pathological situations if they are deregulated. PAI-1 levels correlate with a certain risk 
for thrombotic complications, in-line with statements that PAI-1 is suggested to be the 
main determinant of fibrinolysis 16. PAI-1 is also linked to myocardial infarction and 
obesity 19. A correlation between the metastatic spread of tumors and cardiac fibrosis 
with uPA activity has also been found 19. Additionally, uPAR was found to be related to 
cancer progression 24, and both proteins seem to be involved in inflammatory responses 
25. TPA is reported to be a regulator of inflammatory processes, especially in the 
inflammatory response during ischemia reperfusion injury 26 and recently described in 
stroke 27. 
 A contribution of hemostatic and fibrinolytic events to pathological situations 
becomes even more evident in the case of atherosclerosis, where an extensive 
thrombogenic signal induces thrombus formation causing an eventual occlusion of the 
blood vessel and is followed by severe complications in the vascular system. 
 
 
3.3 Atherosclerosis 
 Cardiovascular diseases, such as myocardial infarction, coronary heart disease, 
ischemic gangrene, abdominal aortic aneurysm, heart failure and stroke are the major 
determinants of morbidity and mortality in the Western world 28, 29. The underlying 
cause of the above-mentioned pathological situations is atherosclerosis, a slowly 
progressive disease of the arteries 30. Risk factors, such as poor diet, low physical 
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activity, smoking, alcohol and stress contribute to the progression of atherosclerosis 31. 
An inflammatory process, in response to lipid retention in the arterial wall, has been 
suggested to represent a hallmark for the initiation as well as the propagation of 
atherosclerosis 28, 32. 
 Cholesterol-rich very low-density lipoprotein (VLDL) and low-density 
lipoprotein (LDL) typify mediators for the initiation of atherosclerosis. As in the case of 
hypercholesterolemia they enter the vascular vessel wall, if their plasma levels are 
excessive 28. In the extravascular space they are usually eliminated, but if their 
concentration is too high they remain stored in the extracellular matrix 33, 34. The 
enzymatic or non-enzymatic oxidation of LDL leads to the generation of bioactive 
lipids, which in turn can activate endothelial cells. Hemodynamic strain represents 
another cause of endothelial cell activation, apart from lipid accumulation. In this case, 
not a high average, but high oscillatory, shear stress is responsible for endothelial cell 
activation 35. 
Activated endothelial cells start to produce and express cell-surface adhesion 
molecules, such as vascular cell adhesion molecule (VCAM)-1 and intracellular 
adhesion molecule (ICAM)-1 together with pro-inflammatory mediators 36. These 
attract cells originating from the blood, including monocytes and lymphocytes, that roll 
on the vascular surface at sites of endothelial activation 28. Subsequently, these blood 
cells adhere and start to infiltrate the underlying vessel wall. Platelets have been 
described to adhere to these regions in addition to mononuclear cells 37. 
 The migration and infiltration by adhered mononuclear cells is regulated 
through chemotactic stimuli. A variety of chemokines (chemotactic cytokines) are 
involved in this process. Macrophage-chemotactic protein (MCP/CCL)-1 and its 
counter-receptor CCR-2 hold crucial roles during the development of atherosclerotic 
lesions 28. Macrophage-colony stimulating factor (M-CSF), interleukin 8 and its 
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receptor CXCR-2 38, as well as other cytokines and chemokines are involved in 
leukocyte infiltration and transformation 39. Infiltrated monocytes will differentiate into 
macrophages, which is a necessary early step in atherosclerosis. Differentiated 
macrophages start to express a special pattern of cell-surface receptors, including 
scavenger receptors (ScRs) and toll-like receptors (TLRs) 40. ScRs are known to exhibit 
a broad range of ligands. They internalize bacterial endotoxins, apoptotic cell fragments 
and oxidized LDL (oxLDL). The excessive uptake of oxLDL leads to a high 
intracellular accumulation of cholesterol, which cannot be mobilized in a sufficient way 
and is therefore stored in cytosolic droplets. Besides ScRs, CD36 also contributes to the 
uptake of modified LDL 41. The uptake of native LDL by macrophages is regulated by 
the membrane receptors LDL receptor (LDLR), VLDL receptor (VLDLR) and LDL 
receptor-related protein (LRP) 41. Despite its rapid down-regulation due to cellular 
cholesterol accumulation, LDLR is important in atherosclerotic development. So is 
VLDLR, which is not down-regulated in response to cholesterol loading, hence, also 
important during atherosclerotic development. LRP expressed on macrophages which is 
involved in a variety of physiological processes, contributes to LDL uptake by 
internalization of apoE-containing LDL 41. Mobilization and efflux of cholesterol from 
macrophages is a process dependent on ATP-binding cassette transporters (ABCs). 
These transmembrane transporters are down-regulated in inflammation, thus 
augmenting the intracellular deposition of cholesterol. Due to the massive uptake of 
cholesterol the macrophages become foam cells, the determinant cell of atherosclerosis 
40. The inflammatory response in developing atherosclerotic plaques might be due, 
additionally in part, dependent on the initiated signaling pathways of TLRs, which lead 
to further macrophage activation 42. 
 Macropinocytosis is another endocytotic process described for epithelial cells, 
fibroblasts, neutrophils and macrophages that occurs constitutively, but slowly 43. In 
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vivo studies have revealed this mechanism to occur in the spleen, lymph nodes and 
liver. Its observation in Kupffer cells, resident macrophages of the liver, is especially 
important. Hence, an occurrence of macropinocytosis in macrophages, transforming 
them into foam cells of atherosclerotic plaques is plausible 41. 
 The result of the uptake of lipids by macrophages and their subsequent 
transformation into foam cells is characterized by fatty streaks 28, 39. The development 
of advanced or complicated atherosclerotic lesions from fatty streaks is the next step in 
atherosclerosis. The fatty streak becomes covered by a fibrous cap consisting of mainly 
VSMC, VSMC-derived collagen, elastin, proteoglycans and extracellular matrix 44. 
This event represents a kind of healing response to injury. VSMC proliferate in 
response to different growth factors 45, 46 and cover the lipid core. The center of an 
atherosclerotic plaque is composed of a mixture of leukocytes, lipids and debris, from 
which conversion into a necrotic core may occur 39. This highly atherogenic area is a 
result of lipid accumulation, apoptosis and necrosis of macrophages and mural cells. An 
atherosclerotic lesion can continuously enlarge at its border, due to uninterrupted 
infiltration of leukocytes, dependent on MCP-1, M-CSF and oxLDL 39. In addition, the 
pericellular localization of uPA, bound to uPAR, may facilitate this migration and 
invasion, as well as extracellular matrix degradation in close proximity to 
macrophages47. 
 Due to plaque rupture, its lipid or necrotic core becomes exposed to blood 
components, such as coagulation factors, especially, FVII. TF, which is highly present 
in the core of an atherosclerotic plaque, forms a complex with FVII and initiates 
thrombus formation. Subsequently, occlusion of the vessel may occur and lead to 
ischemic events in the adjacent organs 39. 
 Plaque rupture usually occurs at its shoulder. The expression rate of matrix-
degrading proteases, such as matrix metalloproteinases (MMPs), is a key determinant in 
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the vulnerability of a plaque 46. MMPs are expressed by activated macrophages in 
response to stimulation by immune and inflammatory cytokines 28. Location of MMP 
expression is often observed in macrophage-rich areas at the shoulders of 
atherosclerotic plaques 46. The latent pro-forms of MMPs are activated by plasmin. 
Active MMPs degrade extracellular matrix components leading to a weakening of the 
fibrous cap 28. Additionally, mast cells respond to inflammatory stimulation, secreting 
proteases and other substances leading to degradation of matrix or inhibition of fibrous 
cap formation 28. Matrix destabilization and reduced fibrous cap formation results in 
reduced thickness and strength of the plaque, finally causing plaque rupture, due to the 
inability to withstand the hemodynamic forces of blood flow 32. 
 There seems to be an important contribution of VSMC to the vulnerability of 
atherosclerotic plaques. Identification of healed plaques led to the investigation of 
further factors involved in plaque stability and immediate repair 44. Apart from 
proteolytic weakening, VSMC-senescence is suggested to be another crucial 
determinant in plaque vulnerability. Senescent cells cannot respond to mitogenic 
stimuli. But proliferation of VSMC is a central event for the repair mechanisms and 
stable construction of atherosclerotic plaques 44. Therefore, senescence caused either by 
exhausting replication or stress in VSMC contributes to plaque instability 44, 48. 
LRP expression in the arterial wall is mainly associated with macrophages and 
VSMC. Besides its role in lipid uptake in macrophages, the LRP-dependent uptake of 
lipids into VSMC and their subsequent transformation into foam cells was recently 
described 49. Lipid uptake in VSMC of atherosclerotic plaques correlates with LRP 
mRNA levels. LRP gene expression is increased in VSMC during atherosclerotic 
development and correlates with pro-thrombotic alteration of the vascular wall 50. These 
VSMC exhibit a lower proliferative response and do not respond to growth factor 
stimulation, but this is not related to reduced survival 49. However, the role of LRP 
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located on the surface of VSMC seems to play miscellaneous roles during 
atherosclerotic development. It is not only been involved in lipid uptake, but also in the 
regulation of growth factor-dependent activation of VSMC and thereby controls the 
integrity of the vascular wall and protects from atherosclerotic lesion formation 51, 52. 
 Atherosclerosis is a complex, inflammatory disease involving a variety of 
mechanisms 53, which lead to a thickening of the arterial wall by accumulation of lipids 
in macrophages that form foam cells. Subsequently, atherosclerotic lesions with a 
fibrous cap and a lipid core emerge, that contain highly thrombogenic material. Stable 
atherosclerotic lesions with a uniformly dense fibrous cap cause cardiovascular 
complications due to the narrowing of the artery. Unstable atherosclerotic plaques are 
often non-occlusive and, therefore, difficult to detect via angiography 39. They cause 
life-threatening complications dependent on their rupture, followed by a thrombotic 
response, resulting in severe complications in the effected organ, such as heart, lung or 
brain 32, 39. 
Atherosclerosis can be related to other diseases caused by a chronic 
inflammatory stimulation, such as cirrhosis of the liver, rheumatoid arthritis in joints, 
glomerulosclerosis in kidney, pulmonary fibrosis in lung and pancreatitis in pancreas 39. 
It also displays the involvement of hemostasis and fibrinolysis, and their deregulation or 
extensive induction due to non-physiological events, resulting in dramatic 
complications for the individual. 
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3.4 Factor VII-activating protease (FSAP) 
Proteolysis is an exquisitely regulated event in vivo which defines the cleavage 
of the appropriate substrate at the right time, location and cellular context. Abnormal 
tuning of endogenous proteolysis causes many life-threatening diseases, such as 
hemophilia, cancer and heart disease 54.  
 
3.4.1 Origin and structure of FSAP 
Like many other proteases that contribute to coagulation or fibrinolysis, FSAP is 
mainly expressed by the liver. Northern blot analysis revealed that the major expression 
is related to the liver, but FSAP mRNA could also be detected in kidney, skeletal 
muscle and pancreas 55. In mice, FSAP mRNA expression is restricted to liver and 
kidney 56. 
 FSAP is a serine protease belonging to the S1 family of Clan PA (cf.: MEROPS 
peptide database; http://merops.sanger.ac.uk/). In the first instance, FSAP was denoted 
as “plasma hyaluronan binding protein” (PHBP), due to its isolation via adsorption to 
an hyaluronic acid column, from plasma 55. The FSAP gene is denoted as hyaluronic 
acid binding protein (habp)-2. Later it was found in a pro-thrombin-complex and 
isolated by the ability to bind to the serine protease inhibitor aprotinin. It was 
demonstrated to activate thrombin specific chromogenic substrates, but was not 
inhibited by hirudin, a specific thrombin inhibitor, and therefore, termed as “plasma 
hyaluronan binding serine protease” (PHBSP) 57. Finally, the observation that FSAP 
can cleave and activate FVII in a TF-independent mechanism led to the denotation 
“factor seven activating protease” (FSAP) 58. 
FSAP protein consists of 560 amino-acids, including a 23 amino-acid signal 
peptide. Structural features of FSAP are similar to those of other serine proteases of the 
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coagulation or fibrinolysis processes. The 237 amino-acid C-terminal region exhibits 
properties of a trypsin-like serine protease domain, whereas the N-terminal region 
consists of three epidermal growth factor-like (EGF) domains and a kringle domain 55 
(Figure 1). 
 Similarities of FSAP gene-structure to other proteases of the hemostasis – 
fibrinolysis system were found and revealed high homology to Factor XII, tPA, uPA 
and hepatocytes growth factor-activator (HGF-A), which are composed in a similar 
fashion like FSAP, exhibiting various kringle and / or EGF domains at the N-terminal 
region and a trypsin-like serine protease domain at the C-terminal end of the amino-acid 
chain 55, 58-60. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Schematic structure of FSAP. Inactive single-chain (sc) conformation (top) and active two-
chain (tc) conformation (bottom) of FSAP with EGF-, kringle and serine protease domains indicated. The 
cleavage site is highlighted by the red arrow, cleavage occurs at R▼I314. Red triangles highlight locations 
of SNP, in either heavy-chain or light-chain. (Modified from 61) 
 
3.4.2 Activation and enzymatic function of FSAP 
 FSAP is secreted by hepatocytes as an inactive zymogen and circulates in 
plasma, requiring activation to become a functioning protease 62, 63. This process is 
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determined by a specific cleavage at position R▼I314, thereby separating the EGF 
domains and the kringle domain from the serine protease domain. Cleavage of FSAP 
generates the active two-chain (tc) conformation from the inactive single-chain (sc) 
conformation 62, 64, 65. The heavy chain contains the three EGF domains and the kringle 
domain, therefore, the light chain only contains the serine protease domain. The two 
chains are held together by a disulfide bridge spanning C301 – C435 62-64. Cleavage at 
position R▼I314 causes a morphological change that opens the access to the active 
center, which is composed of H362, D405 and S509 (Figure 1). 
 Once activated, FSAP is capable of activating other FSAP molecules in an auto-
catalytic fashion. For this mechanism, negatively charged polyanions, such as, heparin 
63, 65, nucleic acids 66, dextran sulfate 63 and polyphosphatidylethanolamine 64 serve as 
cofactors, amplifying the auto-activation efficiency. Subsequently to auto-catalytic 
activation, an auto-degradation occurs, leading to the fragmentation of the FSAP 
molecule, resulting in inactivation 62. 
 Known substrates of FSAP are Factor VII 58, pro-uPA 59, 65, fibrinogen 67, high 
and low molecular weight kininogen 68 and basic fibroblast growth factor (bFGF) 69. 
Additionally, FSAP inhibits platelet-derived growth factor (PDGF)-BB-mediated 
activation VSMC 70. 
 The counterparts of serine proteases are the serine protease inhibitors 
(SERPINs), which regulate the activity of their target proteases in a variety of important 
systems, as demonstrated in the case of hemostasis and fibrinolysis. FSAP is efficiently 
inhibited by C1-inhibtor, α2-AP, inter-α-trypsin inhibitor, AT/heparin, which are 
present in plasma and by aprotinin 71 originating from bovine lunge tissue, formerly 
used in complex surgeries to prevent bleeding. The main function of this kunitz-type 
inhibitor was to slow down the fibrinolysis process, by inhibiting kallikrein and plasmin 
72. Furthermore, FSAP is efficiently inhibited in the lung, by PAI-1 73. 
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3.4.3 Polymorphisms in the FSAP gene 
 Two single nucleotide polymorphisms (SNPs) were identified that cause a single 
amino-acid exchange in the serine protease domain of FSAP. One is called Marburg I 
(MI), which leads to an exchange from Gly to Glu at position 534 (G534E) (Figure 1 and 
2) and the other is called Marburg II (MII), which leads to the change of Gln to Glu at 
position 393 (Q393E) 74 (Figure 1). Two other SNPs also lead to an exchange of a single 
amino-acid, but these SNPs are located in the heavy chain, in the EGF domains. These 
exchanges are S56T and I90V, respectively (Figure 1). Their location in the heavy chain 
suggests no consequences for proteolytic activity. Until today there exist no reports 
raising evidence for changed enzymatic properties caused by these two polymorphisms. 
 About 5 % of the Caucasian populations are carriers of both SNPs, the MI and 
MII, respectively. MI-FSAP exhibits low activating capacity towards pro-uPA, 
compared to wild type (WT)-FSAP, but the activation of Factor VII is not changed 74. 
This suggests that the G534E-genotype of FSAP provokes a shift to a pro-thrombotic 
status. Moreover, the MI-SNP of FSAP was related to late complications of carotid 
stenosis, indicating a direct role for FSAP in atherosclerosis 75. Additionally, MI-FSAP 
was determined as a risk factor in cardiovascular disease in general 76 and associated 
with venous thromboembolism 77. Concerning a relation of MI-FSAP to 
thromboembolism, the observations have recently been discussed critically 78-82. The 
reduction in proteolytic activity, when G is exchanged for E, is most likely due to the 
change in charge around the active center (Figure 2, lower panel, black arrows). The 
relation of MII-FSAP to diseases has not yet been reported. This is, most likely due to 
no changes in proteolytic activity, enzymatic behavior or other functions when MII- is 
compared to WT-FSAP 74. 
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Figure 2: Model structures of WT- and MI-FSAP light chain (serine protease domain). The amino-acid 
sequence from either WT- or MI-FSAP was analyzed using Swiss-model (cf.: 
http://swissmodel.expasy.org/) “First approach mode”. The structure for both FSAP variants was 
generated using the serine protease domain of two-chain tPA (1a5hA) as a template. Upper panel shows 
ribbons with catalytic triad (His362 – Asp405 – Ser509) and the location of MI-SNP (Gly / Glu534) denoted 
by black spots and labels. Lower panel shows the calculated molecule surface with electrostatic potential 
(blue = 3; white = 0; red = -6). Changes dependent on the MI-SNP are highlighted by black arrows. 
Center of the catalytic triad is highlighted by blue arrows. 
 
3.4.4 FSAP and polyanions 
 The mechanism of FSAP activation has not been fully understood yet. The 
interaction with negatively charged polyanions, such as, heparin or RNA 66, accelerates 
the auto-catalytic activation mechanism. The polyanion can bind to latent FSAP and 
thereby changes the conformation of FSAP that leads to activation. Or the polyanion 
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serves as a template for FSAP molecules to bring them in closer proximity, therefore 
promoting the proteolytic activation of latent FSAP. Polyanions exhibit various 
functions in mammalian organisms. 
Especially the polysaccharides, glycosaminoglycans are involved in 
developmental processes 83, 84 as well as in angiogenesis 85 and cancer 86, 87. Their 
interaction with inhibitors of the coagulation cascade, namely, AT and heparin cofactor 
II, is important for the regulation of hemostasis 88 (see page 7). Glycosaminoglycans are 
located on the cell surface, stored in intracellular granules or retained within the 
extracellular matrix, where they can modulate protein functions 89. 
Synthesis of glycosaminoglycans occurs in the Golgi. This process is non-
template driven and involves numerous enzymes that assemble and sulfate the 
glycosaminoglycans. The amount of sulfate groups determines the negative charge 
density of glycosaminoglycans. Several specific patterns of sulfate groups among 
glycosaminoglycans lead to a discrimination of the molecules. Heparin exhibits a more 
dense distribution of sulfate groups than heparan sulfate, leading to a higher negative 
charge density 89. Expression of the glycosaminoglycans varies with cell type; heparin 
is expressed in mast cells and stored in intracellular granules, whereas heparan sulfate is 
ubiquitously found on cell surfaces, but with tissue-specific sulfation patterns.  
Although FSAP was first purified via its binding to hyaluronic acid 55, no 
information is available how hyaluronic acid binds FSAP. Hyaluronic acid exists as 
high MW and low MW polymers. The discrimination is accomplished by the synthesis 
and degradation of hyaluronic acid. High MW hyaluronic acid exhibits anti-angiogenic 
and anti-inflammatory properties, whereas the low MW polymer is pro-angiogenic and 
pro-inflammatory 90-93. Furthermore, content, size and turnover of hyaluronic acid are 
important determinants in atherosclerosis, tissue injury and repair as well as 
angiogenesis and cancer 94, 95. 
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Recently, the contribution of polyphosphates to coagulation has been described 
15. Polyphosphate is a linear polymer of phosphate residues found in many cell types 96-
101. Polyphosphate with an approximate chain length of 70 to 75 residues is stored in 
platelet dense granules 102 and released upon platelet activation. It can activate FV, 
FXII, TFPI 15, 103 and modulate fibrin clot stability 104. The contribution of 
polyphosphate to blood coagulation and its high negative charge density holds evidence 
for a potential interaction with FSAP, similar to heparin. 
Nucleic acids have been described as cofactors for FSAP activation 66, 
especially RNA, which activates FSAP 10 to 100-fold stronger than DNA. RNA has 
been additionally reported to be involved in coagulatory processes 14. At sites of 
massive cell destruction, intracellular RNA might become released and can modulate 
protein functions in this proximity. 
 
3.4.5 FSAP and inhibitors 
 Regulation of FSAP activity can at least partly occur via its inhibition by 
protease inhibitors 71. The SERPINs PAI-1 and protease nexin (PN)-1 can inhibit tPA 
and uPA. PAI-1 is synthesized by many cell types 19, 105 and an important regulator of 
hemostasis and fibrinolysis (see page 9ff). PAI-1-dependent inhibition of its target 
proteases occurs via covalently complex formation. Thereby, the morphology of the 
protease is changed 106. The contribution of PAI-1 to several diseases, such as 
atherosclerosis, tumor angiogenesis or fibrosis was revealed by transgenic mouse 
studies 107. 
 PN-1 is expressed in the brain during development. A constitutive expression in 
the vasculature, by smooth muscle cells and endothelial cells implies contribution to 
vascular homeostasis 108. In hypertension, the expression of PN-1 is increased 109. The 
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inhibition mechanism of PN-1 follows a similar mechanism than that of PAI-1, also 
reported to be dependent on the presence of cofactors 110, 111. In complex with their 
target proteases, PAI-1 and PN-1 can bind to LRP and undergo internalization 112, 113.  
 The presence of PAI-1 and PN-1 in the vasculature and their ability to bind 
polyanions suggests possible interactions with FSAP. The release and expression of 
PAI-1 or PN-1 during pathological situations may indicate a putative regulation of 
FSAP activity within these events. 
  
3.4.6 FSAP in hemostasis & fibrinolysis 
 A high homology of FSAP with proteases of the coagulation and fibrinolysis 
systems, as well as the observation that FSAP activates FVII and pro-uPA suggests a 
function in blood coagulation 58, 59, 71. However, no activation of FSAP could be 
detected subsequently to activation of either the intrinsic or extrinsic coagulation 
pathway 65. Exogenously added FSAP shortened the plasma re-calcification and pro-
thrombin times, but no changes of the activated partial thromboplastin times could be 
observed 71. Fibrinolysis in whole blood is increased via pro-uPA activation by 
exogenously applied FSAP, whereas the exogenous addition of pro-uPA to increase 
fibrinolysis was not associated with activation of endogenous FSAP 65. The activation 
of pro-uPA by FSAP and thereafter plasminogen conversion to plasmin by uPA or a 
direct interaction with uPAR appears to be of higher relevance for the regulation of 
extra-vascular cellular processes and pericellular extracellular matrix remodeling and 
turnover (see page 10ff). 
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3.4.7 FSAP in atherosclerosis 
 Proteases contribute to the microenvironment of atherosclerotic plaques, 
involved in cellular activities as well as extracellular matrix turnover and remodeling 47. 
FSAP antigen has been found in atherosclerotic plaques, particularly detected within 
unstable plaques 114, but no immunostaining was found in normal vessels. The 
distribution throughout the plaque was similar to that of uPA. Defining the co-
localization of FSAP immunostaining with classified areas within the plaques, an 
association mainly with macrophages and to a much lower extend with VSMC was 
observed 114. Not only FSAP antigen could be detected, but also FSAP mRNA was 
localized in unstable atherosclerotic plaques, indicating in situ expression. Monocyte / 
macrophages have been shown to be able to express FSAP as a response to stimulation 
with inflammatory mediators 114. On-site expression as well as possible protein uptake 
and deposition from the circulation raises evidence for a contribution of FSAP in 
atherosclerosis. Although, the association with unstable plaques goes well in-line with a 
suggested increase in overall proteolytic activity and extracellular matrix remodeling, 
the association of MI-FSAP, which is characterized by reduced proteolytic activity 
towards pro-uPA, with cardiovascular disease needs further explanation. 
 The importance of VSMC activation by growth factors, especially PDGF-BB 
within the atherosclerotic plaque has been mentioned before (see page 15ff). FSAP-
dependent inhibition of PDGF-BB-mediated VSMC proliferation and migration 70 in 
vitro, additionally indicates evidence for a contribution of FSAP to plaque behavior and 
shape, considering the relation of VSMC to plaque stability and formation of the 
fibrous cap 44, 115 (see page 15ff). 
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3.4.8 Interaction of FSAP with growth factors 
 FSAP was shown to interact specifically with PDGF-BB-dependent activation 
of VSMC. PDGF-BB is a member of the PDGF-family of growth factors. PDGFs are 
characterized by disulfide bond homo- and heterodimers, exhibiting a conserved 
cystein-knot motive 116, 117. Four gene products form five different members, namely, 
PDGF-AA, PDGF-BB, PDGF-AB 118, 119, PDGF-CC 120 and PDGF-DD 121. The two 
classical members are PDGF-AA and PDGF-BB, which exhibit about 60% sequence 
homology. PDGF-CC and PDGF-DD are newly identified members, which have a 
unique two-domain structure, composed of an N-terminal complement subcomponents 
Clr/Cls, Urchin EGF-like (CUB) domain linked by a hinge region to the conserved C-
terminal PDGF / VEGF growth factor domain 122. The CUB domain determines latency 
and has to be proteolytically removed by extracellular proteases before the ligand can 
bind its receptor 120, 121, 123. 
Two PDGF-receptors (PDGFR) exist, the PDGFRα and the PDGFRβ. PDGF-
AA, PDGF-BB, PDGF-AB and PDGF-CC are ligands for the PDGFRα 119, 120, 124, 125, 
whereas PDGF-BB, and PDGF-DD are ligands for PDGFRβ 121, 123. PDGF-PDGFR-
signaling is involved in many cellular functions. Embryonic development, wound 
healing and the regulation of vascular cells are supposed to be its main scopes 126. 
PDGF expression is increased in atherosclerotic lesions 45. The activation of VSMC 
within atherosclerotic plaques is PDGF-dependent. Further on, the PDGF-system is 
linked to fibrotic diseases and cancer 127. FSAP has been demonstrated to inhibit 
PDGF-BB-dependent activation of VSMC. Thereby, FSAP inhibits PDGF-BB-
mediated proliferation as well as migration of VSMC 70, unraveling it as an inhibitor of 
the pro-atherogenic phenotype of VSMC. These effects of FSAP are dependent on its 
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enzymatic activity, while either addition of an FSAP-blocking antibody or addition of 
inhibitors neutralized its inhibitory effect 70. 
 FSAP also interacts with the bFGF / FGF receptor-1 system which leads to a 
stimulation of the extracellular regulated kinase (ERK) 1 / 2 and phosphoinositol 3 
kinase (PI3K) / Akt signaling pathways in fibroblasts, thereby stimulating their 
proliferation and migration 128. By the release of bFGF, bound to heparan sulfate 
proteoglycans, FSAP induces signaling in human umbilical vein endothelial cells 
(HUVEC) 129. The observations that FSAP cleaves and inactivates bFGF as well as 
allows bFGF-dependent cell activation demonstrate opposing effects of FSAP with 
respect to the regulation of bFGF activity. 
 The influence of FSAP towards vascular cells is restricted to its proteolytic 
activity. This together with the aforementioned association of the MI-polymorphism of 
FSAP with cardiovascular diseases provides reasonable evidence for a contribution of 
FSAP to the regulation of mural cells and the remodeling mechanisms of the 
extracellular matrix during pathophysiological situations. 
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4. Aims of the study 
The work presented herein has been designed to investigate the physiological 
functions of FSAP within the vascular system. In particular, attempts to shed light on 
the mechanisms that regulate FSAP-activity have been undertaken. The defined goals 
were; 
 
1. Characterize in more detail the processes that contribute to FSAP-activation 
and –inhibition. 
 
2. Analyze the potential interaction of FSAP or FSAP-inhibitor complexes with 
cell-surface clearance receptors and the consequences thereof. 
 
3. Define the precise mechanism by which PDGF-BB-dependent signaling is 
inhibited by FSAP. 
 
4. Generate recombinant FSAP-isoforms for structure-function studies. 
 
5. Relate FSAP-function based on these newly obtained findings to different 
disease states, such as atherosclerosis, fibrosis and cancer. 
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5. Material and methods 
5.1 Materials 
 FSAP was prepared from human plasma as described previously 130. In brief, 
human plasma provided from CSL Behring (Marburg, Germany) was filtered, adjusted 
to pH 6.0, 150 mM NaCl and supplemented with aprotinin (CSL Behring) to a final 
concentration of 40 KIU/ml. Subsequently plasma was incubated for 1 h with a mAb 
677-conjugated CNBr-sepharose (GE-Healthcare, Uppsala, Sweden), washed and 
thereafter, bound FSAP was eluted in a single step with the elution buffer (100mM 
glycin, 0.05% Tween 80, 40 KIE/ml aprotinin, pH 2.5). The fraction obtained from the 
antibody column then was supplemented with 20 % glycerol and adjusted to pH 4.5, 
100 mM NaCl. The primed elution then was applied to an anion-exchange column, 
Source 15Q (Amersham Pharmacia, Freiburg, Germany), connected to an EKTA FPLC 
(Amersham Pharmacia). After loading the fraction from the first purification step, the 
anion-exchange column was washed and finally FSAP was eluted with a buffer 
containing 5 mM Na-citrate, 20 mM NaCl, 200 arginin and 200 mM lysine, pH 3.2. 
This buffer was designed to preserve FSAP in its single chain, inactive conformation. 
Subsequent to the elution, pH was adjusted to pH 4.5, the FSAP solution was filter-
sterilized, aliquoted and stored on -80°C. This buffer was used in experiments as a 
negative control. 
Artificial RNA analogue polyinosinic-polycytidylic acid (p(I:C)) and artificial 
DNA analogue polydeoxyinosinic-polydeoxycytidylic acid (p(dI:dC)) were from 
Amersham Pharmacia. Polyphosphate 65- (MW ~ 6600 Da) and 15-mer (MW ~ 1500 
Da) were from Sigma (Munich, Germany) and 35-mer (MW ~ 3500 Da) was from Roth 
(Karlsruhe, Germany). Unfractionated heparin (UH) (MW ~ 15000 Da) was from 
Ratiopharm (Ulm, Germany) or as heparan sulfate, dermatan sulfate, chondroitin sulfate 
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C, LMW heparin (MW ~ 3000 Da), N-acetyl heparin, de-N-sulfated heparin and N-
acetyl-de-O-sulfated heparin (all MW ~ 15000 Da) from Sigma, hyaluronic acid (MW 
~ 100000 Da) from human placenta or rooster comb and biotinylated heparin-albumin 
were from Sigma. Polysialic acid (MW ≤ 38000 Da) was separated from oligosialic 
acid as described before 131 and generously provided by Dr. Sebastian P. Galuska 
(Institute for Biochemistry, Giessen, Germany). Calf intestinal alkaline phosphatase 
(CIAP) was from Fermentas (St. Leon-Rot, Germany). Isolated LRP protein from 
human placenta was generously provided by Dr. Anders Nykjaer (Institute of Medical 
Biochemistry, University of Aarhus, Denmark) 132. PAI-1 was generously provided by 
Dr. Paul Declerck (Katholieke Universiteit, Leuven, Belgium) 133. PN-1 was generously 
provided by Dr. Denis Monard (Friedrich Miescher Institute for Biomedical Research, 
Basel, Switzerland) 134 and AT was from CSL Behring.  
 
5.2 Isolation of platelet-derived polyphosphate and mast cell-derived macromolecular heparin 
Native polyphosphate was extracted with perchloric acid 102 from platelet 
homogenates obtained in the initial steps of a procedure described to isolate dense 
granules 135, using the 19000 x g pelleted material before the separation through density 
gradients and generously provided by Dr. Felix A. Ruiz (Unidad de Investigacion, 
Hospital Universitario Puerta del Mar, Cadiz, Spain). When native polyphosphate was 
used as a cofactor for FSAP activation, polyphosphate 65 and native polyphosphate 
were applied to an OMIX C18 100 µl tip (Varian, Lake Forest, U.S.A.), to further clean 
it from additional contaminations. 
Native macromolecular heparin (MW 750000 Da; range 500000 – 1000000 
MW) was purified from granule remnants of rat serosal mast cells, as described before 
136. Briefly, granule remnants were treated with 2 M KCl to release heparin-bound 
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molecules (notably chymase and other proteases) from heparin proteoglycans and to 
disintegrate the granule remnants into heparin proteoglycan monomers 137. The 
incubation mixture was then applied to a Sepharose 200 column for the isolation and 
separation of heparin proteoglycans. The residual chymase activity in the heparin 
proteoglycan fraction was inhibited with PMSF. Mast cell-derived heparin proteoglycan 
was generously provided by Dr. Petri T. Kovanen (Wihuri Research Institute, Helsinki, 
Finland). 
 
5.3 Cell culture 
Mouse vascular smooth muscle cells (VSMC) were cultured in Iscove’s 
modified medium (IMDM) (Invitrogen, Karlsruhe, Germany) with 10 % (v/v) fetal calf 
serum (FCS) (HyClone, Logan, U.S.A.), 10 U/ml penicillin, 10 µg/ml streptomycin, 2 
mM L-glutamine and 1 mM sodium-pyruvate (Invitrogen, Karlsruhe, Germany). 
WT and LRP-/- mouse embryo fibroblasts (MEF) were cultivated in Dulbecco’s 
modified Eagle’s medium (DMEM) (Invitrogen, Karlsruhe, Germany) with 10% FCS, 
10 U/ml penicillin, 10 µg/ml streptomycin, 2 mM L-glutamine and 1 mM sodium-
pyruvate. Cells were growth arrested in serum-free medium for 18 h prior to 
experiments. 
 
5.4 Plasmids and protein expression 
FSAP MI-SNP (G534E), MII-SNP (E393Q), ΔEGF-3, R313G-cleavage site, H362F-
active site mutants were generated by site-directed mutagenesis of the human wild-type 
FSAP cDNA sequence and subsequently inserted into the EcoRI site of pIRESpuro3 
(BD Biosciences, Heidelberg, Germany). For the ΔEGF-3 mutant, the sequence 
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encoding amino acids 150 to 188 was removed. Plasmids for FSAP-mutants were 
generously provided by Dr. Thomas Weimer (CSL Behring). 
Expression vectors were transfected into human embryonic kidney (HEK)-293 
cells using Lipofectamine 2000 reagent (Invitrogen, Karlsruhe, Germany). Cells were 
grown in DMEM containing 10 % (v/v) FCS (HyClone), 10 U/ml penicillin, 10 µg/ml 
streptomycin, 2 mM L-glutamine and 1 mM sodium-pyruvate. Selection of transformed 
cells was performed in 96-well plates (5000 cells/well) in the presence of 3 µg/ml 
puromycin and 10 µg/ml aprotinin (selection medium). FSAP expression was tested by 
Western blotting using mAB 677 and mAB 1189 (American Diagnostica, Pfungstadt, 
Germany). Percentages of wells (of 96-well plates) were counted to obtain an index of 
the efficiency of clone generation. 
Conditioned medium was prepared with 0.2 % (v/v) FCS and an ELISA was 
used for the quantification of FSAP present in the conditioned media, as described 
before 58. 
 For inducible FSAP expression, FSAP coding sequence was inserted into T-
REx™ expression vector pcDNA4/TO© (Invitrogen), also provided by Dr. Thomas 
Weimer (CSL Behring), transfected into T-REx™-293 cells (Invitrogen) and cultivated 
as described above. Expression was induced with 0.5 µg/ml Tetracycline (Invitrogen). 
 
5.5 Immunocytochemistry 
Cells in 8-well chamber slides (Nunc, Wiesbaden, Germany) were incubated 
with the test substances for the indicated times, washed and fixed with 3.7% (w/v) 
paraformaldehyde, permeabilised with 0.2% (w/v) Triton X-100 (Sigma) and blocked 
with 3% (w/v) BSA (Sigma). After incubation with the primary antibody against FSAP 
(mAb 1189 or mAb 677) (American Diagnostica), LRP (Rabbit polyclonal #2629 
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generously provided by Dr. Dudley Strickland, American Red Cross, Rockville, 
Maryland, U.S.A.), PDGFRβ (Upstate / Millipore, Billerica, MA, U.S.A.) or cleaved 
PARP (#9541) (Cell signaling, Danvers, MA, U.S.A.) 138, secondary antibodies labeled 
with fluoroscein isothiocyanate (FITC) or Rhodamine (Dianova, Hamburg, Germany) 
were used for visualization. Finally, cells were washed and preserved in Vecta-shield 
(Linaris, Wehrtheim-Bettingen, Germany), containing 4’, 6-diamidino-2-phenylindole 
dehydrate (DAPI) to stain the nuclei. Slides were analyzed using a Leica fluorescence 
microscope or confocal spectral laser scanning microscope (Wetzlar, Germany) and the 
images were prepared with the Metamorph software (Visitron, Puchheim, Germany). 
 
5.6 DNA-synthesis assays 
VSMC were stimulated in medium containing 0.2 % (v/v) FCS for 36 h with the 
test substances. During the last 24 h 5-bromo-2-deoxyuridine (BrdU) was added and the 
cells were processed with a BrdU detection kit (Roche Diagnostics, Mannheim, 
Germany) as described by the manufacturer. 
 
5.7 Mitogen activated protein kinase (MAPK)-phosphorylation 
Test samples were preincubated for 60 min in serum-free medium and the cells 
were stimulated for 5 to 15 min. Thereafter, SDS sample buffer, containing 1 mM 
orthovanadate was used to lyse the cells. Phospho-42/44-MAPK antibody (ERK-1/2) 
(Cell Signaling Technology) and an antibody directed against total MAPK (Upstate) 
was used for detection by Western blotting. 
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5.8 Western blot analysis 
Proteins were separated on SDS-polyacrylamide gels and were transferred to 
polyvinylidene fluoride (PVDF) membranes (GE Healthcare). Western blotting was 
performed using enhanced chemiluminescence (ECL) plus reagent (GE Healthcare) as 
described by the manufacturer. For Western blot analysis of FSAP protein a mixture of 
antibodies, directed against the N-terminal (mAb 1189) and C-terminal end (mAb 677), 
was used as described before 70. 
 
5.9 FSAP binding to LRP 
LRP and the respective control buffer containing 2 µg/ml BSA were 
immobilized, in TBS (25 mM Tris-HCl (pH 7.4) and 150 mM NaCl) in a Maxisorp 
plate (Nunc). Thereafter the plate was blocked with 3% (w/v) BSA. Test substances or 
mixtures were preincubated for 30 min prior to their application to the coated wells for 
60 min. FSAP was detected by a monoclonal anti FSAP antibody (mAb 677) followed 
by a horseradish peroxidase (HRP) conjugated secondary antibody (Dako, Glosptrup, 
Denmark). The binding to control buffer containing 2 µg/ml BSA coated wells was 
used as a blank in all experiments and was subtracted to obtain specific binding.  
 
5.10 Expression and purification of receptor associated protein (RAP) 
The constructed plasmid containing His-tag, ampicillin (Amp)-resistance and 
human RAP cDNA was a kind gift from Dr. Willnow (MDC, Berlin, Germany). 
Extracts were purified over a ProBondTM column (Promega, Mannheim, Germany) and 
fractions containing the protein were dialyzed against TBS pH 8.0 containing 5 mM 
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reduced glutathione (GSH) and 1 mM oxidized glutathione (GSSG) (both Sigma) for 
refolding and finally dialyzed against TBS pH 8.0. 
 
5.11 Gel shift assays to detect polyanion binding to FSAP 
6 % to 10 % polyacrylamide – bisacrylamide (37.5:1) native gels were poured in 
Tris Borate EDTA (TBE) (90 mM Tris, 90 mM boric acid, 2 mM EDTA, pH 8.3), with 
or without 6.7 M urea, in a horizontal gel-chamber. 5 µg FSAP was preincubated for 30 
min with or without respective polyanions (10 µg), native sample buffer (TBE with 
sucrose and bromphenol blue) was added and samples loaded on the gel. After 
separation the gel was stained either with toluidine blue to visualize polyanions (data 
not shown) or with coomassie brilliant blue to visualize proteins. 
 
5.12 Competition of heparin binding to immobilized FSAP with various polyanions 
Microtiter plates (Nunc) were coated with 50 µl of a 10 µg/ml FSAP solution in 
100 mM sodium carbonate (pH 9.5) over night (ON) at 4°C. Wells were washed and 
non-specific binding sites were blocked with TBS containing 3 % (w/v) BSA for 60 
min. Biotinylated heparin-albumin (0.5 ng/ml) mixed with dilutions of polyanions was 
allowed to bind for 60 min at room temperature in TBS containing 0.1 % (w/v) BSA, 
after which the plates were washed three times with TBS containing 0.1 % (w/v) 
Tween20 (TBS-T). Bound biotinylated heparin-albumin was detected using HRP-
conjugated streptavidin (DAKO) and immunopure TMB substrate kit (Thermo Fischer 
Scientific, Rockford, U.S.A.). 
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5.13 Binding studies with recombinant FSAP-variants from conditioned media 
Heparin-albumin-biotin (2 µg/ml), PDGF-BB (1 µg/ml) or pAb against FSAP (2 
µg/ml) were immobilized on maxisorp plates in 100 mM sodium carbonate (pH 9.5) 
ON at 4°C. Plates were washed with TBS-T and were blocked with TBS containing 3 
% (w/v) BSA. Conditioned media of the different FSAP-isoforms were allowed to bind 
to heparin-biotin-albumin or PDGF-BB, or pAb. Subsequently plates were washed and 
bound FSAP was detected by the addition of mAb 677 followed by HRP-conjugated 
secondary antibody (DAKO). 
 
5.14 FSAP enzyme activity assay 
To determine activation and enzymatic activity of FSAP, the hydrolysis of the 
chromogenic substrate S-2288 (H-D-isoleucyl-L-prolyl-L-arginine-p-
nitroanilinedihydro-chloride) (Haemochrom, Essen, Germany) at a final concentration 
of 0.2 mM was measured over a time period of 60 min at 37°C in a microplate reader 
EL808 (BioTek Instruments, Winooski, Vermont, U.S.A.) at 405 nm. If the inhibitors, 
PN-1, PAI-1 or aprotinin were used, they were preincubated with FSAP for 10 to 30 
min prior to the enzymatic activity assay. When the assays were performed with 
plasma-derived FSAP, it was used at a final concentration of 1 µg/ml. For the 
measurement of FSAP activity from conditioned media, mAb 677 (2 µg/ml) was 
immobilized in maxisorp plates, blocked with TBS containing 3 % (w/v) BSA and 
washed with TBS-T. The FSAP containing conditioned medium was added to the wells 
to allow FSAP-capture. Finally, the plates were washed and pro-uPA activation was 
measured. The standard assay system consisted of TBS, pro-uPA (1 µg/ml; Saruplase, 
Grünenthal, Stohlberg, Germany) and 0.2 mM of the chromogenic substrate S-2444 (L-
pyroglutamyl-glycyl-L-arginine-p-nitroanilinedihydro-chloride). The change in 
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absorbance was followed over a period of 60 min at 37°C in a microplate reader EL 808 
at 405 nm. To test the FSAP activity directly the conversion of the chromogenic 
substrate S-2288 was determined. Since the direct cleavage of the amidolytic substrate 
is slow, due to the low amount of FSAP in the conditioned media, incubations were 
performed for up to 7 h. Polyanions were used at a concentration of 1 µg/ml in this 
experimental setting. In case of using an inhibitor, it was added to the plates with and 
without polyanion 10 min before adding the chromogenic substrate.  
 
5.15 PDGF-BB cleavage by FSAP 
Cleavage experiments were performed with 125I-PDGF-BB (GE Healthcare) and 
cleavage was followed by SDS-PAGE under reducing conditions (10% v/v β-
mercaptoethanol) and autoradiography. Additionally, recombinant PDGF-BB (R&D 
Systems, Wiesbaden, Germany) was incubated with FSAP in the absence or presence of 
cofactors in TBS. For determining the cleavage sites in the PDGF-B chain the gels were 
blotted onto PVDF membranes and the bands were cut out for further analysis. The 
amino-terminal sequences of the fragments were determined by automated Edman 
degradation using an Applied Biosystems 492 pulsed liquid phase sequencer equipped 
with an on-line 785A phenylthiohydantoin derivative analyzer. Ten cycles of Edman 
degradation were performed. The obtained amino-acids were aligned with the PDGF-B 
chain sequence allowing for detection of multiple N-termini in the preparation. 
 
5.16 Statistical test 
The significance of the results was determined by using an unpaired two tailed 
“t” test. 
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6. Results 
6.1 FSAP is activated by heparin and polyphosphate 
6.1.1 FSAP binding to polyanions 
A unique feature of FSAP is its propensity to bind to negatively charged 
polyanions. The aim is to define which polyanion is important for the activation of 
FSAP. Therefore, the ability of different polyanions to bind to FSAP have been tested. 
This binding represents the first step for the activation of FSAP. The interaction of 
FSAP with polyanions could be shown by the following experimental setups. 
The binding of polyanions to FSAP could alter the electrophoretic mobility of 
both interacting components. Preincubation of FSAP with unfractionated heparin (UH), 
low MW (LMW) heparin, polyphosphate 65 and 35 (polyphosphate of different chain-
length), induced a shift in the mobility of FSAP in polyacrylamide gels with, or without 
urea. Heparan sulfate had a very weak effect and other polyanions had no influence at 
all. When BSA was used as a control, none of the polyanions induced a shift in the BSA 
band (Figure 3). 
To examine whether the different polyanions use the same region in the FSAP 
molecule for binding, competition binding assays where the binding of biotinylated 
heparin to FSAP was measured were performed (Figure 4). UH competed with 
biotinylated heparin for binding to FSAP whereas LMW heparin showed clearly 
diminished ability. All other heparin derivates as well as chondroitin sulfate, were 
completely ineffective (Figure 4, upper panel and data not shown). Polyphosphate 
bound to FSAP in a specific and chain length-dependent manner and competed for the 
binding of biotinylated heparin to FSAP. Dermatan sulfate, polysialic acid, heparan 
sulfate, and hyaluronic acid showed no competition, indicating no binding to FSAP 
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(Figure 4, lower panel and data not shown). Using gel-shift and competition binding 
assays it could be demonstrated that UH binds strongly, LMW weakly, N-acetyl 
heparin, de-N-sulfated heparin, N-acetyl-de-O-sulfated heparin, chondroitin sulfate, 
dermatan sulfate, heparan sulfate and polysialic acid did not bind to FSAP. In contrast 
to earlier studies, hyaluronic acid did not bind to FSAP. Polyphosphate, in a size-
dependent manner, bound to FSAP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Binding of polyanions to FSAP, indicated by a change in electrophoretic mobility. FSAP or 
BSA (5 µg/lane) were preincubated with the respective polyanion (10 µg/lane) for 30 min at RT. Native 
sample buffer was added and samples were directly loaded on gels containing urea (upper panel) or 
native (middle and lower panel) polyacrylamide gels. Shifted bands (complexed FSAP and polyanion) 
indicate the binding of the particular polyanion to FSAP. 
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Figure 4: Binding-competition of different polyanions with heparin-biotin for FSAP. FSAP (10 µg/ml) 
was immobilized and heparin-derivates (upper panel) or other polyanions (lower panel) (0 – 100 µg/ml) 
were mixed with biotinylated heparin-albumin (0.5 ng/ml) and added to the plate. Detection of bound 
biotinylated heparin-albumin was measured by HRP-conjugated streptavidin and TMB substrate. Data is 
shown as % competition of the polyanion with biotinylated heparin-albumin (mean ± SEM, n = 4). 
 
6.1.2 Activation of FSAP by different polyanions 
Ensuing a binding of polyanions to FSAP, this interaction may increase the 
auto-catalytic activation of FSAP. Assessing different variations of heparin and other 
polyanions will specify the requirements for this mechanism. Next all the polyanions 
described above have been analyzed with respect to their abilities to activate FSAP. UH 
was a strong activator whereas LMW heparin activated FSAP to a smaller extent, and 
all other tested heparin-derivates exhibited no activation (Figure 5, upper panel). 
Polyphosphate showed potent activation of FSAP to the same extent as UH in a chain 
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length-dependent manner. Heparan sulfate and dermatan sulfate showed weak 
activation of FSAP at high concentrations (Figure 5, middle panel). Polysialic acid and 
hyaluronic acid did not activate FSAP (Figure 5, lower panel). To show the specificity 
of the polyphosphate effect it was degraded with a phosphatase (Figure 6C). The 
polyphosphate-associated accelerating effect on FSAP-activity was decreased by 
phosphatase pretreatment in a time- (Figure 6A) and dose-dependent (Figure 6B) 
manner. As a control, it could be observed that phosphatase treatment did not influence 
UH-mediated activation of FSAP (Figure 6). These studies showed that FSAP auto-
activation is efficiently increased by UH, by LMW heparin to lower extent, while 
glycosaminoglycans have a weak effect. N-acetyl heparin, de-N-sulfated heparin, N-
acetyl-de-O-sulfated heparin, polysialic acid and hyaluronic acid, again, totally failed to 
increase FSAP activity. Polyphosphate accelerated the FSAP auto-activation in a 
comparable fashion to UH. Overall, the pattern of binding of polyanions to FSAP was 
identical to the pattern of their ability to activate FSAP. 
To quantify the ability of heparin or polyphosphate to activate FSAP, the values 
for KM and vmax towards the chromogenic substrate S-2288 were measured. The KM 
was reduced when heparin or polyphosphate were present, but not significantly, 
whereas vmax was significantly increased by 5-fold when heparin and 6-fold when 
polyphosphate was present (Figure 7). The difference between heparin and 
polyphosphate with respect to FSAP activation was not significant, but obvious 
(p=0.1031). Compared to KM where no difference could be observed (Figure 7). 
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Figure 5: FSAP activity dependent on the presence of different polyanions. Polyanions in the range of 
0.01 – 100 µg/ml were added to FSAP (1 µg/ml), and FSAP-activity (mmOD · min-1) was determined, 
with the conversion of the chromogenic substrate S-2288 (mean ± SEM, n = 4). 
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Figure 6: Effect of phosphatase pretreatment on polyphosphate-dependent activation of FSAP. (A) 
Polyphosphate 65 or heparin (1 µg/ml) was incubated in 50 mM Tris (pH 9.5) for 0 – 8 h on 37°C with 1 
U/ml CIAP. Then polyphosphate or heparin – CIAP solution was added to FSAP or (B) 1 µg/ml 
polyphosphate 65 or heparin was incubated with CIAP in the concentration range of 0.1 – 1 U/ml in 50 
mM Tris (pH 9.5) for 4 h on 37°C and subsequently added to FSAP. The FSAP-activity was measured 
with the conversion of chromogenic substrate S-2288 (mean ± SEM, n = 3, similar results have been 
obtained from 2 independent experiments). (C) To visualize degradation of polyP, 5 µg polyP 65 or 
heparin was incubated for 4 h on 37°C in 50 mM Tris (pH 9.5) with CIAP (0.1 – 2 U). CIAP-treated 
polyP and heparin was run on a urea-gel and stained with toluidine blue. 
 
 
0
5
10 
15 
20 
0 0.1 0.4 0.6 0.8 1 
CIAP [U/ml] 
B 
0 0.1 0.2 0.3 0.4 0.5 1 2 2 2 0 CIAP [U]: 
polyphosphate 65 UH 
C 
0
4
8
12 
16 
0 0.5 1 2 3 4 5 6 7 8 8 [h] 
CIAP
A 
FS
A
P
-a
ct
iv
ity
 (m
m
O
D
 · 
m
in
-1
 a
t 4
05
nm
) 
heparin (UH) 
polyphosphate 65 
no cofactor 
6. Results                                                                          The role of FSAP in vascular pathophysiology 
 
 
 
- 46 -
 
 
 
 
 
 
 
 
Figure 7: Lineweaver-Burke-Plot for KM and vmax-determination of FSAP with cofactors. FSAP activity 
was measured with a concentration range of the substrate S-2288 (10 – 150 µM) without cofactor 
(circles), with heparin (squares) or polyphosphate (triangle)(both 1 µg/ml). Values for KM or vmax were 
determined by linear regression. Figure shows one representative example of 4 experiments (n = 3) with 
similar results. * indicates p<0.05 versus control. 
6.1.3 Polyanions as cofactors for the inhibition of FSAP by SERPINs 
The regulation of FSAP activity occurs via specific inhibition by inhibitors 
present in the circulation or adjacent tissue. One class of inhibitors are the SERPINs. A 
contribution of polyanions to FSAP regulation by this class of inhibitors was 
investigated. SERPINs exhibit enhanced or altered substrate specificity in the presence 
of cofactors 139. PAI-1 and PN-1 neutralized the enzymatic activity of FSAP as 
measured by the direct chromogenic substrate S-2288 (Figure 8A). Complete inhibition 
at lower concentrations was achieved with PAI-1 compared to PN-1, whereas heparin 
was needed as a cofactor in case of PAI-1. The formation of complexes between FSAP 
and PN-1 or PAI-1 could be observed in a dose dependent manner with Western 
blotting (Figure 8B). To examine the cofactor function of polyanions with respect to 
FSAP inhibition, active tc-FSAP was preincubated with PAI-1 or AT with or without 
different concentrations of polyanions. Inhibition of FSAP by PAI-1 was increased by 
UH, LMW heparin and to a lower extent by N-acetyl heparin (Figure 9A, upper panel). 
Polyphosphate exhibits a strong cofactor function for the inhibition of FSAP by PAI-1 
in a chain length-dependent manner. Heparan sulfate was a cofactor at high 
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concentrations (Figure 9A, lower panel), dermatan sulfate and polysialic acid at even 
higher concentrations (data not shown) while hyaluronic acid exhibited no effect at all 
(Figure 9A, lower panel). In the case of inhibition of FSAP by AT only UH and 
heparan sulfate were able to serve as cofactors (Figure 9B). Polyphosphate and other 
tested polyanions showed no cofactor properties for the AT-dependent FSAP inhibition 
(Figure 9B, and data not shown). LMW heparin, N-acetyl heparin (Figure 9B, upper 
panel) and polyphosphate (Figure 9B, lower panel) increased the activity of FSAP even 
in the presence of AT. There was a difference in the cofactor effect of polyanions with 
respect to inhibition of FSAP by PAI-1 and AT.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: FSAP interaction with PN-1 or PAI-1. (A) FSAP (1 µg/ml) was preincubated for 30 min with 
either PN-1 (0 – 2 µg/ml) (left panel) or PAI-1 (0 – 1 µg/ml) (right panel) without (closed circles) or with 
(open circles) heparin (10 µg/ml) (mean ± SD, n = 3). Thereafter, FSAP activity was measured via the 
conversion of S-2288. (B) FSAP (30 ng/lane) was preincubated with PN-1 (upper panel), in the 
concentration range 10 – 80 ng/lane, or PAI-1 (lower panel) in the concentration range 1 – 50 ng/lane. 
Western blot analysis was performed using two monoclonal antibodies against FSAP. Single FSAP and 
FSAP-inhibitor complexes are indicated by arrows. 
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Figure 9: FSAP inhibition by PAI-1 or AT, dependent on the different polyanions. FSAP (1 µg/ml) was 
preincubated either with PAI-1 (1 µg/ml) (A) or with AT (5 µg/ml) (B) for 30 min without, or with 
heparin-derivates (upper panels) or other polyanions (lower panels) in the concentration range of 0.01 – 
100 µg/ml. FSAP-activity (mmOD · min-1) was determined and inhibition was calculated as % to FSAP-
activity without inhibitor (mean ± SEM, n = 4). 
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Only UH and related molecules are cofactors for inhibition with AT, whereas 
UH and related molecules, as well as polyphosphate, are cofactors for inhibition by 
PAI-1. The more detailed analysis of PAI-1-dependent inhibition of FSAP with respect 
to the cofactor function of UH and polyphosphate 65 revealed that the IC50 of PAI-1, at 
the given conditions, was reduced to 50 % by UH and polyphosphate 65 (Figure 10). 
 
 
 
 
 
 
 
 
 
Figure 10: IC50-values for PAI-1-dependent FSAP inhibition. FSAP (1 µg/ml ≡ 15 nM) was incubated 
with PAI-1 in the concentration range of 5 – 150 nM (≡ 0.23 – 7 µg/ml), without co-factor or with 
heparin or polyphosphate 65, for 30 min at RT. FSAP-activity (mmOD · min-1) was determined and 
calculated to % of FSAP activity without inhibitor. The inhibitory efficiency of PAI-1 for the inhibition 
of FSAP is increased by 1.98 ± 0.2 fold in the presence of UH and 2.23 ± 0.28 fold in the presence of 
polyphosphate 65 (mean ± SEM, n = 3, figure shows one representative of 5 independent experiments 
with similar results). 
 
6.1.4 Polyphosphate as a cofactor for the FSAP-dependent inhibition of VSMC proliferation 
VSMC proliferation is a critical event in numerous diseases 127, 140. Therefore, a 
regulation of VSMC activation is of high interest. It was recently shown by us that 
inhibition of VSMC proliferation by FSAP occurs through a specific proteolytic 
cleavage of PDGF-BB 70, 141, and that this mechanism is promoted by heparin or RNA 
142. Identification of other cofactors among the investigated polyanions opens new gates 
for the physiological relevance of FSAP-dependent PDGF-BB inhibition. Now it could 
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be observed that LMW heparin and heparan sulfate also increased the inhibitory effect 
of FSAP on VSMC proliferation, but to a lower extent compared to UH. Polyphosphate 
also promoted the inhibitory effect of FSAP on VSMC proliferation, whereas de-N-
sulfate heparin and hyaluronic acid were ineffective (Figure 11). The ability of the 
different polyanions to inhibit cell proliferation matched with the pattern of FSAP 
binding and activation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Cofactor function of polyanions on FSAP-dependent inhibition of PDGF-BB-mediated VSMC 
activation. PDGF-BB (20 ng/ml) was preincubated without (grey columns) or with (black columns) 
FSAP (0.25 µg/ml) and 1 µg/ml (upper level) or 10 µg/ml (lower panel) of the different polyanions for 1 
h at 37°C in serum free medium. Subsequently, VSMC were stimulated for 36 h in medium containing 
0.2 % FCS. DNA-synthesis was measured (mean ± SD, n = 3) using a kit detecting BrdU incorporation 
into newly synthesized DNA. 
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6.1.5 Assessment of native heparin and native polyphosphate as cofactors for FSAP function 
UH isolated from skin and synthetic polyphosphate demonstrated the most 
effective cofactor function among all investigated polyanions. The confirmation of 
these observations with natural material will strengthen their physiological contribution 
to FSAP regulation. Mast cell-derived macromolecular heparin and platelet-derived 
polyphosphate were isolated as native substances and tested for their interaction with 
FSAP. The mast cell-derived heparin bound to FSAP as indicated by a shift in mobility 
in native polyacrylamide gel (Figure 12A) and, when compared to UH, native heparin 
was even more efficient with respect to competition of biotinylated heparin binding to 
immobilized FSAP (Figure 12B, left panel) and FSAP-activation (Figure 12C, left 
panel). As shown by the mobility shift assay polyphosphate isolated from platelets also 
bound FSAP (Figure 12A) and more efficiently competed with biotinylated heparin for 
the binding to immobilized FSAP, than its synthetic analogue polyphosphate 65 (Figure 
12B, right panel). The activation of FSAP by native polyphosphate was much lower 
when compared to the synthetic material (Figure 12C, right panel). Taken together, 
mast cell-derived heparin was identical to UH in all aspects investigated, but there were 
differences between platelet-derived and synthetic polyphosphate. 
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Figure 12: Assessment of native mast cell-derived heparin or platelet-derived polyphosphate with respect 
to cofactor function. (A) FSAP (5 µg/lane) was preincubated with unfractionated heparin (UH), native 
heparin, polyphosphate 65 or native polyphosphate (each 2 µg/lane) and directly loaded to native 
polyacrylamide gel. Shifted bands (complexed FSAP) indicate binding of the respective polyanion to 
FSAP. (B) FSAP (10 µg/ml) was immobilized and synthetic or native heparin (0.05 – 10 µg/ml) (B, left 
panel) as well as synthetic or native polyphosphate (0.033 – 5 µg/ml) (B, right panel) were mixed with 
biotinylated heparin-albumin (0.5 ng/ml) and added to the plate. Bound biotinylated heparin-albumin was 
measured by POD-conjugated streptavidin and TMB substrate (mean ± SD, n = 3). (C, left panel) 
Unfractionated heparin (0.01 – 10 µg/ml), native heparin (0.02 – 5 µg/ml) or (C, right panel) synthetic or 
native polyphosphate (0.01 – 2.5 µg/ml) was added to FSAP (1 µg/ml). FSAP-activity (mmOD · min-1) 
was determined (mean ± SD, n = 3). 
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6.2 FSAP-inhibitor complexes are internalized via LRP 
6.2.1 Binding of the FSAP-inhibitor complexes to LRP 
The scavenger and signaling receptor LRP is involved in atherosclerosis and 
other diseases 50, 51, 143. The LRP-dependent internalization of protease-protease 
inhibitor complexes represents an important feature of LRP 112, 113, 144. Therefore, the 
interest was high in a potential interaction of either FSAP or FSAP in complex with its 
inhibitors with LRP. PAI-1 and PN-1 are SERPINs produced locally in the vessel wall. 
FSAP-PN-1 complex showed a strong specific binding whereas FSAP-PAI-1 complex 
showed weaker binding and FSAP by itself, or in complex with aprotinin (data not 
shown), exhibited no binding at all to LRP (Figure 13). Concentration-dependent 
analysis confirmed that FSAP-PN-1 complex has a higher affinity for LRP compared to 
the FSAP-PAI-1 complex (Figure 13A). The binding of FSAP-PN-1 complex could be 
inhibited with either the addition of heparin (Figure 13B) or receptor associated protein 
(RAP), a 39 kDa LRP antagonist, known to inhibit ligand binding to LRP 145 (Figure 
13C). Maximal inhibition (≈ 70%) was observed with 10 μg/ml heparin or RAP (data 
not shown). Therefore this concentration was used in the following experiments. 
 
6.2.2 Binding of FSAP-PN-1and PAI-1 complexes to LRP on cells 
To demonstrate that the binding of FSAP inhibitor complexes, shown with isolated 
proteins (Figure 13), to LRP holds true also under more physiological conditions LRP-
bearing VSMC or WT and LRP-/- mouse embryo fibroblasts (MEF) were used. The 
binding of FSAP, FSAP-PN-1 or FSAP-PAI-1 complexes to cells was analyzed with 
immunofluorescence microscopy. Application of FSAP alone to VSMC did not lead to 
an accumulation of cellular FSAP, whereas FSAP-PN-1 or FSAP-PAI-1 complexes 
were internalized by VSMC (Figure 14). 
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Figure 13: FSAP-inhibitor complexes binding to LRP (isolated protein). (A) FSAP (1 µg/ml) was 
preincubated with PN-1 (closed circles) or PAI-1 (open circles) in the concentration range of 0 – 2 µg/ml 
for 30 min to allow complex formation and binding of the FSAP-inhibitor complexes to immobilized 
LRP (1 µg/ml) was measured by specific monoclonal antibody against FSAP. To demonstrate the 
influence of heparin (B) or RAP (C) (both 10 µg/ml) for FSAP-inhibitor complexes binding to LRP, 
FSAP binding was measured as before. FSAP was preincubated with PN-1 or PAI-1 (2 µg/ml) in the 
absence (dark bars) or the presence (white bars) of heparin (B), or without (dark bars) or with RAP 
(striped bars) (C) (mean ± SD, n = 3). 
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Co-staining of FSAP (green) and LRP (red) on VSMC shows a co-localization 
of the ligand and the receptor in the intracellular compartment. Time course analysis 
showed that FSAP-PN-1 complexes were internalized within minutes (Figure 14A). 
More FSAP-PN-1 complexes were internalized by VSMC compared to FSAP-PAI-1 
complexes in line with the observed binding characteristics to isolated LRP in vitro 
(Figure 14B). Preincubation of VSMC with RAP prior to application of FSAP-PN-1 
complex completely inhibited the internalization of the complex and the co-localization 
of FSAP and LRP (Figure 14C). FSAP-PN-1 complexes but not FSAP alone were 
internalized by WT-MEF but not by LRP-/- MEF (Figure 14D) and this was observed 
irrespective of the fixation procedure used (data not shown). FSAP-inhibitor complex 
binds to LRP, is internalized by the scavenger receptor and is directed to lysosomes. 
Although FSAP has been efficiently inhibited by PAI-1 or PN-1, differences 
concerning the binding of the respective FSAP-inhibitor complexes to LRP could be 
observed. FSAP complexed with PN-1 exhibited stronger binding to LRP than FSAP 
complexed with PAI-1. Studies on uPA-inhibitor complexes have not shown such 
differences 144. However, with respect to leukocyte adhesion, opposing effects of either 
uPA-PN-1 or uPA-PAI-1 complexes have been demonstrated 146.  
The herein shown disparity between FSAP complexed with PN-1 or PAI-1 
might be due to the fact that PAI-1 requires cofactors, such as heparin for an efficient 
inhibition of its targets 139, whereas PN-1 not. Heparin inhibits binding to LRP. 
Therefore, in our LRP-binding studies no heparin was present. This explains the 
observed lower binding capability, due to a reduced formation of FSAP-PAI-1 
complexes under these conditions. 
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Figure 14: Intracellular detection of FSAP-inhibitor complexes in VSMC and MEF. FSAP (1 µg/ml) was 
preincubated with PN-1 or PAI-1 (2 µg/ml) and applied to VSMC. Internalization of FSAP was detected 
by immunostaining using a monoclonal antibody (mAb 1189) for FSAP, indicated in green, and LRP, 
indicated in red, co-localization is indicated by yellow color and highlighted by white arrows. (A) Cells 
were fixed after the indicated time points (5 – 60 min) and intracellular FSAP was evaluated. (B) The 
difference between FSAP in complex with PN-1, or PAI-1 was evaluated by internalized FSAP after 60 
min. (C) Visualization of the inhibitory effect of RAP towards LRP-dependent internalization of FSAP-
PN-1 complexes. (D) FSAP internalization in LRP+/+ and LRP-/- MEF. Nuclei were stained with DAPI, 
scale bars = 20 µm. 
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6.2.3 Effect of FSAP-PN-1 complex on PDGF-BB-induced receptor activation 
Since FSAP is a strong inhibitor of the PDGF-BB signaling pathway and LRP is 
involved in modulating the same pathway the interactions between FSAP, LRP and 
PDGFRβ were investigated. With respect to a potential influence of FSAP-PN-1 
complexes to LRP-dependent PDGFRβ handling the cellular arrangement of PDGFRβ 
was investigated. In unstimulated cells PDGFRβ is diffusely distributed over the whole 
cell membrane and upon stimulation with PDGF-BB internalization of PDGFRβ into 
lysosomes is observed (Figure 15) as has been described before 147. This PDGF-BB-
induced internalization of PDGFRβ was not influenced by the presence of FSAP-PN-1 
complex (Figure 15, upper panel). Hence, FSAP-PN-1 complexes are internalized via 
LRP but this does not influence the internalization of PDGF-BB-PDGFRβ by LRP even 
though there was co-localization of FSAP-PN-1 complex (green) with internalized 
PDGFRβ (red) (Figure 15, lower panel). Because of a diffuse distribution of PDGFRβ, 
as in unstimulated cells 148, no staining was observed when PDGF-BB was preincubated 
with FSAP alone due to a cleavage and inactivation of PDGF-BB. Although FSAP-PN-
1 complexes as well as the PDGF-BB-PDGFRβ complexes bind to LRP their 
internalization was completely independent of each other. 
 
6.2.4 Effect of FSAP-PN-1 complex on PDGF-BB-dependent cell activation 
No influence of FSAP-PN-1 with respect to an altered cellular trafficking of 
PDGFRβ was observed. To confirm the suggested independence of FSAP-PN-1 
clearance and PDGFRβ internalization by LRP, the potential influence of FSAP-PN-1 
complexes on PDGF-BB-mediated signal transduction have been analyzed.  
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Figure 15: FSAP-PN-1 complexes co-localize with internalized PDGFRβ. PDGF-BB was preincubated 
without, or with FSAP (1 µg/ml), PN-1 (2 µg/ml) or FSAP + PN-1 for 1 h before addition to VSMC. 
PDGFRβ is indicated in red, internalized FSAP is indicated in green. White arrows highlight activated 
and subsequently internalized PDGFRβ (upper panel). Yellow color represents co-localization of 
PDGFRβ and FSAP, highlighted by white arrows (lower panel). Nuclei were stained with DAPI. Scale 
bars = 20 µm. 
 
Preincubation with FSAP-PN-1 did not alter PDGF-BB-mediated 
phosphorylation of 42/44-MAPK in VSMC (Figure 16A). Inhibition of the proteolytic 
activity of FSAP by PN-1 led to neutralization of its ability to inhibit PDGF-BB-
mediated DNA synthesis (Figure 16B). Neither RAP nor FSAP-PN-1 complex had any 
significant influence on PDGF-BB-mediated DNA-synthesis indicating that LRP is not 
regulatory under these conditions on these cells. 
Generally, more PDGFRβ was present in LRP-/- MEF than in WT MEF (Figure 
17C) and higher levels of tyrosine phosphorylation were observed in LRP-/- MEF than 
in WT MEF after PDGF-BB stimulation (Figure 17B). These results confirm the known 
role of LRP in regulating PDGF-BB activity. No effect of FSAP-PN-1 complex was 
observed on this pattern of expression or phosphorylation of PDGFRβ.  
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Figure 16: Influence of FSAP-PN-1 complexes on PDGF-BB-dependent cell activation. (A) In serum-free 
medium containing heparin (10 µg/ml) VSMC were stimulated with PDGF-BB (20 ng/ml), PDGF-BB 
preincubated with FSAP ( 1 µg/ml) or PDGF-BB preincubated with FSAP-PN-1 complex in the absence 
or presence of RAP (10 µg/ml) for 15 min. Western blot analysis was performed using a monoclonal 
antibody against phospho 42/44 MAPK. As a loading control a polyclonal antibody against total MAPK 
was used on the stripped membrane. (B) As in the above experiment VSMC were stimulated in the 
absence (gray column) or presence of RAP (10 µg/ml) (open column). DNA-synthesis was measured 
(mean + SD, n = 3) using a kit to measure BrdU incorporation into newly synthesized DNA. 
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Figure 17: LRP-dependent PDGFRβ distribution and activation. 1 µg/ml FSAP and 2 µg/ml PN-1 were 
preincubated for 30 min. 20 ng/ml PDGF BB was then preincubated with either buffer, FSAP or FSAP-
PN-1 for 60 min and the mixtures were used for stimulating cells for 10 min. MEF lysates were 
processed for Western Blot analysis. Heavy chain and light chain of LRP is expressed in LRP+/+ MEF but 
not in LRP-/- MEF (A). Since LRP internalizes PDGFRβ, more PDGFRβ is present in LRP-/- than LRP+/+ 
cell (C). Stimulation of cells with PDGF-BB leads to tyrosine phosphorylation of PDGFRβ (B) and its 
internalization and degradation (C). FSAP or FSAP-PN-1 complex do not influence this process. Actin 
blot shows equal loading of cell extracts in all lanes (D). 
 
6.3 FSAP cleaves PDGF-BB at distinct sites 
6.3.1 A cluster of basic residues is the target motif for FSAP-dependent cleavage of PDGF-BB 
FSAP inhibits PDGF-BB-dependent signaling by a proteolytic mechanism. To 
specify this process the generated PDGF-BB fragments were analyzed for their amino-
acid sequences. Thereby the precise cleavage sites of FSAP were identified. Fragments 
of cleaved PDGF-BB (Figure 18A) were resolved by SDS-PAGE and blotted onto 
PVDF membranes and analyzed by amino-terminal sequencing (Figure 18A).This led 
to the determination of preferential proteolytic sites after amino-acid R113, R160 and 
K161. R113 is a known cleavage site in PDGF-BB and natural fragments starting at this 
point are found in platelets but the responsible protease was unknown149. The latter two 
cleavage sites are in loop III of PDGF-BB, important for receptor binding and 
activation150 (Figure 18B). 
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Figure 18: Determination of FSAP 
cleavage-site in the PDGF-BB molecule. 
(A) PDGF-BB (20 μg/ml) was incubated 
with FSAP (200 μg/ml) in the presence of 
heparin or poly (I:C) (10 μg/ml) as 
indicated for 60 min at 37oC. SDS-PAGE 
was performed under reducing conditions 
and the protein fragments were detected by 
silver-staining or were blotted onto a PVDF 
membrane and stained with Coomassie 
blue (Data not shown). Bands were 
analysed by amino-terminal sequencing. 
Molecular mass standards are indicated in 
kDa. The results of the N-terminal 
sequencing are shown and the complete 
sequence of PDGF-B chain is marked with 
the FSAP-cleavage sites. (B) Swiss-model 
generated structure of PDGF-B (1pdgA). 
Blue arrows highlight FSAP cleavage sites. 
Location of loop III region, important for 
receptor binding, and of the conserved 
cystein – knot structures are given. 
 
6.3.2 Nucleic acids are cofactors for FSAP-mediated cleavage of PDGF-BB 
It has been previously shown that FSAP cleaves PDGF-BB in a dose- and time-
dependent manner in the presence of the cofactor heparin. Here the relation of nucleic 
acids with respect to FSAP-dependent PDGF-BB cleavage could be evaluated. The 
fragmentation of PDGF-BB was only discernable under reducing conditions, and not 
under non-reducing conditions (Figure 18). This indicates that after limited proteolysis 
the PDGF fragments were held together through disulphide bridges and that the 
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antibody binding site was intact141. 125I-PDGF-BB cleavage was determined in the 
presence of natural RNA, DNA as well as synthetic poly (I:C) or synthetic poly (dI:dC). 
Natural or artificial RNA was a more effective cofactor for the cleavage of PDGF-BB 
than DNA (Figure 19A, B). This effect was dependent on the concentration of RNA 
(Figure 19A, B) and could be inhibited by protease inhibitors (Figure 19C). These 
results suggest that RNA is an effective cofactor for the limited proteolysis of PDGF-
BB by FSAP, in line with its propensity to increase auto-activation of FSAP 66. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Cleavage of PDGF-BB by FSAP is enhanced by nucleic acids. (A) 125I-PDGF-BB was 
incubated with FSAP (1 µg/ml) in the presence of heparin (10 µg/ml), natural RNA or natural DNA for 
60 min at 37oC. (B) Same as above except that poly (I:C) or poly (dI:dC) were used as cofactors. (C) 
Similarly, FSAP was compared to inactivated PPACK-FSAP, or FSAP in the presence of the protease 
inhibitor aprotinin (2 µg/ml) or protease-nexin-1 (8 µg/ml) in the presence of poly (I:C) or heparin (each 
10 μg/ml). After SDS-PAGE under reducing conditions autoradiography was performed. 
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6.4 Structure-function analysis using recombinant FSAP-mutants 
6.4.1 Expression of recombinant FSAP-isoforms in HEK-293 cells 
Different FSAP-variations were produced to investigate mechanisms of FSAP 
activation and inhibition in more detail. The evaluation of recombinant FSAP 
expression will be a basis for a large-scale production later on. Recombinant WT-
FSAP, MI- and MII-FSAP was generated to proof the functionality of the recombinant 
versions. Furthermore, two isoforms that were suggested to be completely inactive were 
produced, the cleavage-site mutant R313G and the active-site mutant H363F. To 
investigate the binding of polyanions to FSAP, a FSAP-variation that lacks the EGF-3 
domain (ΔEGF-3-FSAP), which is the putative polyanion binding-site, was generated. 
The highest number of stably transfected clones were obtained with vector 
control, R313G cleavage site mutant, H362F active site mutant and MI SNP, whereas the 
number of clones obtained with WT, ΔEGF-3 and MII was very low (Figure 20A). 
Amount of FSAP in the conditioned media was the highest in R313G, H362F and MI, 
whereas WT, ΔEGF-3 and MII contained very low levels of FSAP protein, empty 
vector exhibited no expression of FSAP (Figure 20B). To equalize and standardize 
these differences in FSAP concentration for further experiments, the amounts were 
calibrated using ELISA and Western blotting (Figure 20C). These results show that the 
number of stable clones generated as well as the amount of protein produced increased 
with decreasing proteolytic activity of the FSAP variants. 
To further understand why fewer clones with WT-FSAP compared to the 
inactive mutants were obtained, FSAP immunocytochemistry on cells transfected with 
WT-, MI- and ΔEGF-3-FSAP plasmids were performed. WT-FSAP appeared as a 
dense irregular structure within the cytoplasm, whereas MI- and R313G-FSAP (Figure 
21A) exhibited a more granular and dispersed localization. Initially, the number of cells 
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transfected with WT-FSAP was similar to those transfected with FSAP variants, 
exhibiting lower or no enzymatic activity. Hence, it was reasoned that cells expressing 
WT-FSAP had a selective disadvantage or died, leading to fewer viable cells. To test 
this point more systematically an inducible expression system was used. Without 
induction, the expression of FSAP and staining for the apoptosis marker, cleaved PARP 
138 was negligible. With the induction of FSAP expression there was a concomitant 
increase in cleaved PARP staining. Addition of tetracycline to cells transfected with the 
control vector did not show any alterations in FSAP or cleaved PARP staining (Figure 
21B). As a control, the expression of a related protease, uPA, was efficiently expressed 
and did not induce apoptosis. 
 
6.4.2 Interaction of FSAP-isoforms with heparin 
Polyanion binding to FSAP is important for a subsequent activation of the 
zymogen. Using the recombinant FSAP-variations it was possible to study this 
relationship in more detail. Previous studies have alluded to the necessity of FSAP 
EGF-3 domain in heparin to binding 151. The ΔEGF-3 variant, lacking the EGF-3 
domain, exhibits a clearly diminished ability to bind heparin (Figure 22A). The 
recombinant proteins WT-, MI-, and R313G-FSAP (Figure 22A) as well as MII- and 
H362F-FSAP (data not shown) bound to a similar extent to immobilized heparin. As a 
control the binding of WT-, ΔEGF-3-, MI- and R313G-FSAP to immobilized pAb 
against FSAP was similar (Figure 22B). Using recombinant protein lacking the EGF-3 
domain confirmed its importance for binding to heparin. Heparin binding leads to an 
auto-activation of latent FSAP 62. WT- and ΔEGF-3-FSAP exhibited a similar 
amidolytic activity without the addition of heparin whereas MI- and R313G-FSAP 
exhibited no activity (Figure 23A, black symbols). After addition of heparin, the 
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activity of WT- and MI-FSAP was increased 1.5-fold, whereas the activity of ΔEGF-3-
FSAP remained unchanged (Figure 23A, white symbols). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Expression of FSAP isoforms in HEK-293 cells. (A) After transfection of cells and transfer 
into selection medium, the percentage of wells with viable clones was determined. (B) The amount of 
FSAP in conditioned medium, was determined by ELISA (mean ± SD, n = 3). (C) Supernatants of 
different FSAP variants, standardized by ELISA, were analyzed by Western blotting performed with a 
mixture of mAb 677 and mAb 1189. 
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Figure 21: Cellular effects of over-expressed FSAP-variants. (A) Confocal microscopy of transiently 
transfected HEK-293 cells with empty vector, WT-, MI- and R313G-FSAP. FSAP was stained using mAb 
1189 (red) and nuclei with DAPI (blue). White arrows highlight staining for FSAP. (B) Transiently 
transfected T-REx™-293 cells with control vector or vector carrying WT-FSAP, cultivated in growth 
medium with or without 0.5 µg/ml tetracycline. FSAP is indicated in red, cleaved PARP in green and 
nuclei in blue. White arrows indicate staining for cleaved PARP. Calibration bars = 20 µm. 
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PAI-1 is known to inhibit FSAP efficiently in the presence a cofactor 152. PAI-1-
dependent inhibition of WT-, but not ΔEGF-3-FSAP was increased by heparin (Figure 
23B). Hence, the EGF-3 domain is not only important for heparin binding but 
contributes largely to the heparin mediated activation as well as the inhibition of FSAP 
by PAI-1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: Binding characteristics 
of FSAP-isoforms to heparin. 
(0.003 – 0.06 µg/ml) WT- (closed 
circles), ΔEGF-3- (open circles), 
MI- (grey circles) and R313G-
FSAP (closed triangles) was 
allowed to bind to (A) heparin-
biotin-albumin (2 µg/ml) or (B) a 
polyclonal antibody for FSAP. 
Binding was measured with mAb 
677 against FSAP (mean ± SD, n 
= 3). 
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Figure 23: Characterization of the enzymatic activity of different FSAP-isoforms. (A) WT- (circles), 
ΔEGF-3- (squares), MI- (triangles) and R313G-FSAP (diamonds) (0.06 µg/ml) was captured with mAb 
677. FSAP activity without (closed symbols) or with (open symbols) heparin (1 µg/ml) was measured by 
the conversion of S-2288, mean ± SEM (n=3). (B) FSAP inhibition by PAI-1 (0.01 µg/ml), without 
(closed column) and with (open column) heparin (1 µg/ml), mean ± SEM (n = 3), * indicates p < 0.005, 
using unpaired two tailed “t” test. (C) FSAP isoforms (0.003 – 0.06 µg/ml) were captured as described 
above and pro-uPA (1 µg/ml) activation without (closed symbols) or with (open symbols) heparin 
(1µg/ml) was measured by the conversion of S-2444 (mean ± SEM, n = 4 – 6). 
 
6.4.3 Pro-uPA activation by FSAP-isoforms 
Pro-uPA is efficiently activated by FSAP 71. Therefore, its activation by 
different FSAP-isoforms was tested. WT-FSAP activated pro-uPA more effectively 
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3-FSAP by 2-fold only (Figure 23C, white symbols). MII-FSAP exhibited a 
comparable activity to WT-FSAP, whereas R313G- and H362F-FSAP showed no activity 
towards pro-uPA as would be predicted (Figure 23C). The same pattern could be 
observed with respect to pro-uPA cleavage by FSAP-isoforms, using Western blotting. 
FSAP-isoform-dependent uPA-β-chain generation was inhibited by PN-1 or PAI-1 
(Figure 24) 
 
 
 
 
 
 
 
 
Figure 24: Pro-uPA cleavage by FSAP-isoforms. Western blot analysis of pro-uPA (100 ng/lane) 
incubated with different FSAP-isoform conditioned media with heparin (10 µg/ml) alone or with PN-1 or 
PAI-1 (both 25 ng/lane). SDS-Page was performed under reducing conditions and uPA bands were 
detected using a polyclonal anti uPA antibody. Arrows indicate pro-uPA and after cleavage appearing 
uPA-β-chain. 
 
6.4.4 Binding to and cleavage of PDGF-BB by FSAP-isoforms 
Besides pro-uPA, PDGF-BB is another important substrate of FSAP vascular 
tissues 141. PDGF-BB is cleaved by FSAP at distinct sites 142. Polyanions, such as 
heparin or RNA are important cofactors for this mechanism (Figure 19). Using 
recombinant FSAP-variations the importance of FSAP EGF-3 domain for FSAP-
dependent PDGF-BB inhibition was analyzed. The reduced ability of MI-FSAP to 
inhibit PDGF-BB signaling 141 was additionally analyzed with the recombinant 
mutants. Without heparin the binding of WT-, ΔEGF-3- and R313G-FSAP to PDGF-BB 
was low. This binding was increased with heparin in case of WT-and R313G-FSAP, but 
not for ΔEGF-3-FSAP indicating again the importance of the EGF-3 domain of FSAP 
(Figure 25A). Cleavage of 125I-PDGF-BB was detected by WT- and plasma-derived 
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FSAP, but not by ΔEGF-3- or MI-FSAP either in the absence or presence of heparin 
(Figure 25B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: Binding to and cleavage of PDGF-BB by FSAP-isoforms. WT-, ΔEGF-3- and R313G-FSAP 
(0.06 µg/ml) were added to immobilized PDGF-BB. Binding of FSAP-isoforms without (closed 
columns) or with (open column) heparin (10 µg/ml) was determined with a FSAP antibody, mean ± SD 
(n=3). FSAP binding to PDGF-BB was normalized with respect to FSAP binding to polyclonal anti-
FSAP Ab. (B) Autoradiogram of cleaved 125I-PDGF-BB by WT-, ΔEGF-3-, MI-, R313G- or from plasma 
derived FSAP. Arrows indicate intact- and cleaved-125I-PDGF-BB. 
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7. Discussion 
 The correlation of the MI-single nucleotide polymorphism (G534E) of FSAP 
with cardiovascular diseases 61, 75, 76 and its reduced proteolytic activity 74, indicate the 
functional importance of FSAP. Smooth muscle cells contribute to the development of 
atherosclerotic lesions 51, 115, and are major effectors in restenotic processes, post 
balloon-angioplasty and stent implantation 140. Since FSAP is able to inhibit VSMC 
proliferation in vitro 70 and in vivo 141, FSAP is of crucial importance to the 
development of vascular diseases. Additionally, FSAP protein and mRNA were found 
in atherosclerotic plaques 114, demonstrating FSAP’s importance for the development of 
atherosclerotic lesions. The evaluation of the regulation of FSAP activity will provide 
new insights for novel therapeutic approaches in the treatment of cardiovascular and 
related diseases. 
 
7.1 Activation of FSAP 
 It is not known which events lead to the activation of FSAP in the vasculature. 
This prompted us to investigate different forms of heparin and other polyanions present 
in the vascular system with respect to FSAP activation. When assessing the different 
heparin isoforms (unfractionated heparin, LMW heparin, N-acetyl heparin, de-N-sulfate 
heparin and N-acetyl-de-O-sulfate heparin) with respect to their ability to bind to and 
activate FSAP, strong effects only with unfractionated heparin were observed. The 
interaction of heparin with FSAP was found to be dependent on its molecular size and 
even more on its negative charge density. LMW heparin, which exhibits reduced size 
but comparable negative charge density, showed only weak effects. However, heparin 
variations exhibiting the same size and reduced negative charge density (N-acetyl 
heparin, de-N-sulfate heparin and N-acetyl-de-O-sulfate heparin), showed no effect at 
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all, except for heparan sulfate, which activated FSAP at high concentrations. These 
observations demonstrate that FSAP activation by heparin-like molecules can only 
occur at sites of glycosaminoglycans that exhibit a high rate of sulfation. Hence, the 
known release of heparin by mast cells within atherosclerotic lesions 153 may represent 
a functional situation in which FSAP activation occurs. This represents a process 
limited to a specified location and time. After their stimulation, mast cells secrete a 
variety of factors, including heparin, and thereby contribute to the development of 
atherosclerotic lesions. To test the native material with respect to binding to and 
activation of FSAP mast cell-derived heparin has been analyzed. Native mast cell-
derived heparin exhibited the same features as the synthetic heparin. Thus, the relation 
of heparin within atherosclerotic plaques to a potential FSAP activation could be 
confirmed using native material. 
Another highly charged negative molecule is polyphosphate, which has been 
recently reported to activate the contact factor pathway, FV, TFPI 15, and to modulate 
fibrin clot structure 104. Synthetic polyphosphate of different average molecular sizes 
and phosphatase-treated polyphosphate have been used to activate FSAP. 
Polyphosphate, in a similar way to heparin, binds to and activates FSAP in a size-
dependent manner. Polyphosphate is stored in the platelete’s dense granules 102 and 
released upon platelet activation. The localization of polyphosphate to the events of 
hemostasis and fibrinolysis raises considerable indirect evidence for a physiological 
contribution of polyphosphate to the activation process of FSAP. In order to test this 
conjecture, isolated native platelet-derived polyphosphate was used with respect to 
FSAP binding and activation. Platelet-derived polyphosphate exhibited anomalous 
properties. While the binding of platelet-derived polyphosphate to FSAP was as 
expected, activation studies reported only a very weak ability of native polyphosphate 
to activate FSAP. This anomaly may have occurred because the synthetic 
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polyphosphate exhibits a relatively heterogeneous chain-size distribution, with up to 
200 phosphate residues, whereas the native platelet-derived polyphosphate is restricted 
to chain-lengths of 70 to 75 units 102, 154. Since our investigation is one of the first in 
comparing native polyphosphate with its synthetic analog, no other reports are available 
at this time. 
Platelets contribute to the development of atherosclerotic plaques, because 
activated platelets secrete various inflammatory cytokines 37. After the establishment of 
the atherosclerotic plaque, platelets are important for the hemostatic response after 
plaque rupture. Polyphosphate released from activated platelets, either during blood 
coagulation or during the development of atherosclerotic lesions, represents a putative 
activator for FSAP within these distinct events. Polyphosphate released by platelets 
exhibit a strong potential to interact with FSAP and locate possible activation of the 
latent zymogen in pathophysiological situations. These findings are in agreement with 
the observation that the FSAP-antigen is located in atherosclerotic plaques. Further 
studies are needed to explain why native polyphosphate has different properties 
compared to synthetic polyphosphate and how this relates to FSAP activation in 
physiological situations. 
Since FSAP is able to inhibit PDGF-BB-dependent cell activation and VSMC 
are important in the development of atherosclerotic plaques, the interest as to whether 
heparin or polyphosphates enable PDGF-BB inhibition by FSAP was high. Both 
polyanions demonstrate a strong cofactor function with respect to FSAP-dependent 
PDGF-BB inhibition. This mechanism represents another possible function for FSAP 
activation within atherosclerotic plaques, regulating the activation of VSMC. 
Apart from heparin, it has been found that nucleic acids, especially RNA, can 
serve as a cofactor for the auto-catalytic activation of FSAP 66. After more detailed 
studies, it could be confirmed that RNA or its synthetic analog poly (I:C), but not DNA 
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or poly (dI:dC), are efficient cofactors for FSAP-dependent inhibition of PDGF-BB-
mediated VSMC activation. These findings and the fact that FSAP protects RNA from 
enzymatic breakdown may provide an additional possible activation mechanism at sites 
of cell destruction that occur in areas of atherosclerotic lesions 155 or disruption of the 
endothelial cell layer where blood coagulation is initiated. Similar to heparin and 
polyphosphate, RNA released from cells will locally activate FSAP that in turn can 
regulate PDGF-BB-dependent cell stimulation. 
 
7.2 Inhibition of FSAP 
 While FSAP is efficiently inhibited by SERPINs, the effect of the different 
polyanions in respect to their contribution to FSAP regulation by inhibitors was 
investigated. AT is strongly dependent on the presence of heparin or heparan sulfate to 
interact with its targets FIIa and FXa 3. Only unfractionated heparin exhibited a cofactor 
function for the AT-dependent inhibition of FSAP. This indicates a potential regulation 
of FSAP activity via AT at sites where mast cells have secreted unfractionated heparin 
or to circumstances where unfractionated heparin was administered exogenously. PAI-1 
was reported to require cofactors for the efficient inhibition of its target proteases 139. In 
this regard, RNA was recently demonstrated to serve as a cofactor for PAI-1-dependent 
inhibition of FSAP, whereas heparin was not 73. Here it could be shown that 
unfractionated heparin as well as polyphosphate serve as efficient cofactors for the 
inhibition of FSAP by PAI-1. Heparan sulfate, due to its reduced negative charge 
density, is a cofactor for PAI-1 only at high concentrations. These findings would 
indicate a minor role for heparan sulfate with respect to FSAP-regulation in vivo. 
Similar to the potential to activate FSAP, the inhibition of FSAP by AT or PAI-1 is 
limited to sites where a cofactor is present. AT-dependent inhibition of FSAP appears 
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to be of less importance, since approximately 5-fold more AT is required to achieve the 
same inhibition efficiency as with PAI-1. However, AT is constitutively present at high 
concentrations in the circulation, which would still suggest a contribution to the 
regulation of FSAP activity. PAI-1, in addition to its constitutive expression, is released 
by activated platelets 21. Therefore, similar to polyphosphate, it is present during the 
development of atherosclerotic lesions, in the case of plaque rupture and of initiated 
blood coagulation. Thus, PAI-1 appears to be of importance for the regulation of FSAP 
activation at sites of platelet activation. 
The regulation of FSAP activity by inhibitors present in the vasculature is an 
important mechanism to abrogate FSAP activity and prevent excessive proteolytic 
degradation. PN-1 is up-regulated in hypertension 109 and, like PAI-1 156, during 
atherosclerosis 146. Recent studies revealed that macrophages and platelets are the major 
source of PN-1 within atherosclerotic plaques 108. Despite studies that have shown that 
PN-1 activity is regulated by cofactors 110, 134, FSAP is efficiently inhibited by PN-1 
independently of any cofactor 152. The physiological regulation of FSAP via either PAI-
1 or PN-1 is evident, since the inhibitors, FSAP and cofactors are detected in close 
proximity during all stages of atherosclerotic lesion development. 
 
7.3 Internalization of FSAP 
LRP is part of the LDL receptor family and has a large number of different 
ligands, including proteases, protease-protease-inhibitor complexes, lipids and -
cellsurface receptors 113, 143, 157, 158. Bound ligands become internalized and directed to 
early endosomes for subsequent lysosomal degradation, whereas LRP is recycled back 
to the cell membrane 112, 159, 160. In mouse models of atherosclerosis, LRP was shown to 
be a protective molecule with respect to atherosclerotic lesion development 50-52, 161, 162. 
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LRP is involved in the regulation of the PDGF-BB-PDGFRβ signaling axis, by 
internalizing the activated PDGFRβ. Thereby, LRP abrogates the PDGF-BB-dependent 
cell activation 160, 163. Apart from the LRP-dependent uptake of lipids and its regulation 
of PDGF-BB-signaling, LRP also was shown to interact with proteases, especially 
hemostasis factors and their inhibitors 113. Therefore, the possibility of an interaction for 
FSAP or FSAP-inhibitor complexes with the scavenger receptor, LRP was investigated. 
It could be demonstrated that FSAP in complex with either PN-1 or PAI-1 
specifically binds to LRP. This could be shown with, either isolated LRP protein or 
with LRP present on cell-surfaces. FSAP-Inhibitor complex binding to LRP was 
efficiently inhibited by the addition of the LRP antagonist RAP 164, 165, which confirmed 
a specific binding. This conclusion could be further strengthened by the observation 
that FSAP-inhibitor complexes were not internalized in LRP-deficient fibroblasts. 
 Since LRP interacts directly with the PDGF-BB-PDGFRβ signaling cascade, by 
internalizing the activated receptor and also by binding directly to PDGF-BB, thereby 
undergoing intracellular phosphorylation 166 which generates an Shc-docking site and 
subsequently propagates signal transduction 166, 167. An alteration of LRP-function 
following its interaction with FSAP-inhibitor complexes was predicted. The occurrence 
of FSAP-inhibitor complexes that bind to LRP might thereby block LRP for other 
binding partners. This would mean that the inhibition of FSAP by PN-1 or PAI-1 would 
not only preserve PDGF-BB signaling by inhibiting FSAP-dependent cleavage, but also 
due to the binding of FSAP-inhibitor complexes to LRP the internalization of activated 
PDGFRβ would be slowed down. Therefore, PDGF-BB-signaling would be prolonged. 
In these studies, an intracellular co-localization of FSAP with PDGFRβ was observed 
when PDGF-BB signaling occurred. If PDGF-BB was cleaved by FSAP, no 
intracellular staining of FSAP or PDGFRβ was observed. The distribution of PDGFRβ 
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throughout the cell-surface is diffuse in unstimulated cells. Therefore, no membrane-
localization for quiescent PDGFRβ is detectable 148. 
The presence of FSAP-PN-1 complexes exhibited no effect on PDGF-BB-
PDGFRβ signaling, indicating that the LRP-internalization system is a high capacity 
system, which is not easily saturated. Another explanation could be that the binding of 
FSAP-PN-1 complexes to LRP occurs at another epitope than the one for PDGF-BB or 
PDGFRβ within the LRP molecule. It might also be possible that the binding happens 
in different cellular compartments. Therefore, there appears to be no effect of FSAP 
complexed with SERPINs with respect to an alteration of the PDGF-BB signaling 
cascade 152. 
 
7.4 FSAP-dependent inhibition of PDGF-BB 
The inhibitory effect of FSAP on PDGF-BB is strongly dependent on 
proteolytic processing. Therefore, the interest in the existence and location of putative 
FSAP cleavage-sites within the PDGF-BB molecule was high. 
The family of platelet-derived growth factors has been studied extensively, and 
the molecular structure of PDGF-BB has been revealed by crystallography 168. The 
important region in PDGF-BB and PDGF-AA for their binding to and activation of 
their receptors has been reported as a cluster of cationic amino-acid residues Arg159-
Lys160-Lys161 169, located in the so-called loop III region 150. 
Usually the regulation of PDGF-BB activity happens via its secretion or on its 
release from cell membranes or the extracellular matrix 170. Another mechanism that 
controls the signaling of PDGF-BB is the internalization of its activated receptor, 
PDGFRβ. LRP and α2-MG receptor represent important candidates for this regulation 
of PDGF-BB signaling 51, 171. PDGF-BB signaling is also regulated via other signaling 
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molecules, such as the hyaluronan-dependent activation of its receptor CD44. This 
process inhibits PDGF-BB-mediated cell activation by involvement of an intracellular 
tyrosine phosphatase 172. Another mechanism dependent on the activation of PAR-1 by 
FIIa inhibits PDGF-BB-induced migration of fibroblasts 173. While this mechanism is 
controlled by the proteolytic activity of FIIa, it is not a direct function towards the 
PDGF-BB or PDGFRβ molecules. For periodontal cells, a regulation mechanism that 
directly affects the PDGFRβ molecule has been recently described. PDGFRβ is 
proteolytically cleaved by elastase, which leads to the inhibition of PDGF-BB-mediated 
cell activation 174. Proteolytically modified PDGF-BB was found in platelets, but this 
modification exhibits no altered mitogenic activity 149. Studies on recombinant PDGF-
BB revealed a proteolytic cleavage site of PDGF-BB at position R113, whilst proteinase-
resistant mutations exhibited increased secretion levels and higher mitogenic activity 
than the cleavage-susceptible variants 175, 176. The proteases responsible for this 
processing at R113 have not yet been identified. 
Our data, have shown for the first time, a direct effect of a protease on the 
PDGF-BB molecule which results in the complete inhibition of PDGF-BB-dependent 
signal transduction. The determination of FSAP cleavage sites in PDGF-BB by N-
terminal sequencing revealed two distinct sites. The first cleavage site is located at 
R▼T114, which is a reported natural cleavage site in PDGF-BB. PDGF-BB which has 
been processed in this way represents 30 % of that found in platelets 149. The second 
cleavage site of FSAP in PDGF-BB is located directly in the loop III region: 
Arg▼Lys▼Lys161 (RKK-motif). PDGF-BB-cleavage by FSAP in this region which is 
vital for the activation of its downstream receptor PDGFRβ, explains the inhibitory 
action of FSAP towards PDGF-BB-dependent cell activation. However, PDGF-AA 
does not seem to be cleaved by FSAP, although it exhibits the same amino-acid 
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sequence as PDGF-BB in the loop III region, so not only the primary sequence but the 
neighboring sequences as well as the overall accessibility are important. 
Since MI-FSAP is correlated with vascular diseases in its attribute of reduced 
proteolytic activity, it could be shown that MI-FSAP, in contrast to WT-FSAP, was not 
able to inhibit neointima formation in a mouse model 141. Neointima formation or 
restenosis occur following stent implantation or balloon angioplasty 140, therefore, 
represent late complications for patients with a myocardial infarction. The narrowing of 
the lumen is, at least in part, dependent on PDGF-BB-mediated activation of VSMC. 
With this finding, the contribution of FSAP in atherosclerotic development and also to 
restenosis, a mechanism characterized by extensive VSMC proliferation has been 
elucidated. The inhibition of neointima formation is dependent on FSAP’s proteolytic 
activity. This together with the fact that FSAP specifically cleaves PDGF-BB raises the 
possibility that FSAP may regulate other diseases also characterized by excessive cell 
stimulation dependent on PDGF-BB signaling.  
Fibrotic diseases, such as liver or lung fibrosis, are at least partially driven by 
PDGF-BB signaling 126, 177, 178, hence a beneficial effect of exogenously applied FSAP 
is most likely. Newly generated blood vessels have to be stabilized by pericytes and 
later on by smooth muscle cells. Both these mechanisms are dependent on PDGF-BB 
signaling 126, 179, 180. The investigation as to whether exogenously applied FSAP will 
interfere with angiogenic stimuli, e.g., in cancer-driven angiogenesis, will reveal 
potentially new functions or therapeutic medication possibilities for FSAP. In general, 
all diseases which are accompanied by extensive proliferation of cells that become 
activated by PDGF-BB are potential target treatments for FSAP. 
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7.5 Expression of recombinant FSAP 
Recombinant FSAP variants were produced to gain more insight into the 
regulation and function of FSAP. Our first observation was that enzymatically inactive 
FSAP-mutants (active-site mutant, cleavage-site mutant, MI-FSAP) generated a high 
number of stably transfected clones. Whereas the selection of enzymatically active WT, 
MII- and ΔEGF-3 FSAP transfected cells generated very low numbers of viable clones. 
These results are in agreement with the measurement of secreted FSAP by the different 
mutants, which was high for inactive and low for active FSAP mutants. 
Furthermore, the intracellular appearance of active FSAP-mutants compared to 
inactive variants differed. WT-FSAP was present in a dense-staining pattern, suggesting 
intracellular accumulation, whereas inactive mutants appeared in a regularly dispersed, 
granular pattern. Cells that expressed WT-FSAP showed signs of apoptosis, suggesting 
that intracellular accumulation and toxicity for host cells are dependent on FSAP 
enzymatic activity. A possible explanation for these cytotoxic effects might be due to 
the interaction of FSAP with nucleic acids 66, as in the recently described function for 
FSAP of nucleosome proteolysis in apoptotic cells 181. Over-expression of other serine 
proteases, such as uPA, did not show any of these effects (unpublished observations). 
The restriction of this pro-apoptotic effect to enzymatically active FSAP suggests that 
FSAP cleaves or activates defined proteins within cells. If these affected proteins are of 
crucial importance in cellular mechanisms, such as gene-expression, cell-cycle 
regulation, metabolism or apoptotic regulation, the cell-death ensues. Usually FSAP is 
almost exclusively expressed in hepatocytes, which potentially have a specialized 
mechanism for the expression and secretion of proteases. Therefore, hepatocytes should 
be tested for the expression of recombinant FSAP and analyzed with respect to 
apoptotic events dependent on the enzymatic activity of FSAP. 
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Recombinant WT-FSAP was similar to plasma-derived, isolated FSAP. The 
enzymatic activity of recombinant MI-FSAP was, in line with results obtained from MI-
FSAP purified from human plasma 74, 141, very low. MII-FSAP, which also exhibits an 
amino-acid exchange located in the serine protease domain, showed no change in 
enzymatic properties when compared to WT-FSAP. The two point-mutation variants, 
cleavage-site (R313G) and active-site (H362F) mutant were as expected, completely 
inactive. In order to perform structure-studies it is a prerequisite to produce large 
amounts of recombinant FSAP. Here the foundation for such production has been laid. 
Studies on proteolytic FSAP fragments 151, showed that the EGF-3 domain is 
important for the binding of cofactors to FSAP. When using the binding competition 
assay and from older studies, one could conclude that heparin, RNA and polyphosphate 
use the same binding region in the FSAP molecule, namely the EGF-3 domain. The 
FSAP-isoform that lacks the EGF-3 domain is not activated by polyanions to the same 
efficiency as WT-FSAP. A strong effect of heparin and polyphosphate in the context of 
PAI-1-dependent inhibition of FSAP was observed. As expected, this effect was 
abolished when the inhibition of ΔEGF-3-FSAP by PAI-1 was measured. Hence, a 
crucial role for the EGF-3 domain with respect to regulation of FSAP activity has been 
confirmed. 
 
7.6 Conclusion 
With the herein presented data new findings that shed light on the complex 
regulatory mechanism of FSAP activation, inhibition and turnover are provided.  
The ability of FSAP to inhibit PDGF-BB-dependent cell activation is the first 
mechanism of its kind to be described. Therefore, it is concluded that FSAP is 
important for the regulation of PDGF-BB activity in the vasculature. Since PDGF-BB 
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signaling has been reported in many diseases, a correlation with the MI-SNP of FSAP 
in respect to the occurrence of diseases or the type of their progression should be 
investigated. Thus, FSAP represents a possible new protein with a high potential that 
can be used for therapeutic applications to treat atherosclerosis, fibrosis, cancer and 
other related diseases (Figure 26). 
 
Figure 26: Summarizing scheme. Latent FSAP is secreted by the liver and undergoes auto-catalytic 
activation, which is amplified by negatively charged polyanions, such as, polyphosphate or heparin. The 
active FSAP is efficiently inhibited by serine protease inhibitors (SERPINs), such as PAI-1 and PN-1 and 
thereafter, the complexes can bind to LRP and undergo internalization. FSAP is a potent inhibitor of 
PDGF-BB-mediated cell activation, whereas the MI-FSAP SNP exhibits reduced proteolytic activity and 
therefore, is not able to inhibit PDGF-BB signaling. Hence, FSAP contributes to the development of 
vascular diseases, such as atherosclerosis and restenosis through its regulation of PDGF-BB signaling. 
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8. Summary 
 The functions of factor VII activating protease (FSAP) in the vascular system 
have been investigated. Marburg I (MI)-FSAP-polymorphism correlates with various 
vascular diseases and is characterized by a reduced proteolytic activity. Hence, the 
activity of FSAP appears to be of pivotal importance in vascular homeostasis. Further 
evidence for the contribution of FSAP to vascular pathophysiology was provided by the 
fact that FSAP-antigen and mRNA have been found within atherosclerotic plaques. 
FSAP circulates as an inactive zymogen in plasma and is activated by negatively 
charged polyanions. However, the precise mechanisms of FSAP-activation have not yet 
been elucidated. FSAP is known to inhibit platelet-derived growth factor (PDGF)-BB-
mediated cell activation, whilst PDGF-BB is an important factor in the development of 
atherosclerosis and contributes to other fibrotic and cancer-related diseases. 
FSAP has been shown to be activated by heparin and RNA. Herein it has been 
demonstrated that polyphosphate, released by activated platelets, is a newly detected 
cofactor for FSAP. The high negative charge-to-size ratio and overall molecular size of 
polyanions qualify them as cofactors for FSAP. Furthermore, by using recombinant 
ΔEGF-3-FSAP, the importance of FSAP’s EGF-3 domain in its interaction with 
polyanions could be confirmed. Heparin is released by mast cells, polyphosphate by 
platelets and RNA might be released from dying cells. Therefore, these cofactors can be 
present at sites of atherosclerosis and regulate FSAP function in these circumstances. 
FSAP is inhibited by serine protease inhibitors, such as protease nexin (PN)-1, 
plasminogen activator inhibitor (PAI)-1 and antithrombin III. If FSAP was complexed 
with either PN-1 or PAI-1 its internalization in a LDL receptor-related protein (LRP)-
dependent mechanism by smooth muscle cells and fibroblasts could be shown. Hence, 
LRP accounts for the clearance of FSAP-inhibitor complexes. The functionality of LRP 
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is crucial in the regulation of PDGF-BB signaling. However, the interaction of FSAP-
inhibitor complexes with LRP had no impact on the LRP-mediated regulation of 
PDGF-BB signal-transduction. 
 The inhibitory effect of FSAP on PDGF-BB-dependent cell activation occurs 
through specific cleavage of the PDGF-BB molecule. The cleavage-sites of FSAP in the 
PDGF-BB molecule have been identified. This revealed that FSAP-dependent cleavage 
had destroyed the receptor binding motif of PDGF-BB. Hence, the reduced proteolytic 
activity of MI-FSAP is the determinant for its correlation with vascular diseases, which 
has been demonstrated by its inability to inhibit PDGF-BB-dependent smooth muscle 
cell activation. 
 With the herein presented results, new insights into the complex mechanisms 
that are involved in FSAP-regulation have been created. The improved description of 
these mechanisms may lead to novel therapeutic approaches in the treatment of fibro-
proliferative, cancer-related and atherosclerotic diseases. 
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9. Exposé 
Die Aufgaben der Faktor VII aktivierenden Protease (FSAP) im vaskulären 
System wurden untersucht. Der Marburg I (MI)-FSAP Polymorphismus zeigt eine 
Verbindung zu verschiedenen vaskulären Erkrankungen auf, und zeichnet sich durch 
eine verringerte enzymatische Aktivität aus. Daraus wird ersichtlich, dass die Aktivität 
der FSAP von entscheidender Bedeutung für die vaskuläre Homeostase ist. Weitere 
Hinweise auf eine Verbindung zur vaskulären Pathophysiologie wurden durch die 
Tatsache, dass Protein und mRNA der FSAP in arteriosklerotischen Plaques gefunden 
wurden, geliefert. Die FSAP zirkuliert als inaktives Zymogen im Plasma und wird von 
negativ geladenen Polyanionen aktiviert. Die genauen Mechanismen zur Aktivierung 
der FSAP sind jedoch noch nicht aufgeklärt. Es ist bekannt, dass die FSAP die platelet-
derived growth factor (PDGF)-BB abhängige Zellaktivierung inhibiert, während PDGF-
BB ein wichtiger Faktor für die Entstehung von Arteriosklerose, und beteiligt an 
fibrotischen und krebs-assoziierten Erkrankungen, ist. 
Es wurde gezeigt, dass die FSAP von Heparin und RNA aktiviert wird. Hier 
wird nun demonstriert, dass Polyphosphat, welches von aktivierten Thrombozyten 
freigesetzt wird, ein neu entdeckter Kofaktor der FSAP ist. Ein hohes Verhältnis von 
negativer Ladung zur Größe und die allgemeine molekulare Größe qualifizieren 
Polyanionen zu Kofaktoren der FSAP. Weiterführend konnte, durch die Verwendung 
von rekombinantem ΔEGF-3-FSAP, die Bedeutung der FSAP-EGF-3 Domäne, für ihre 
Interaktion mit Polyanionen, bestätigt werden. Heparin wird von Mastzellen freigesetzt, 
Polyphosphate von Thrombozyten und RNA könnte von sterbenden Zellen freigesetzt 
werden. Demnach können diese Kofaktoren in Bereichen von Arteriosklerose 
vorhanden sein und dort die Funktionen der FSAP regulieren. 
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Die FSAP wird durch Serinprotease Inhibitoren wie Protease Nexin (PN)-1, 
Plasminogen Aktivator Inhibitor (PAI)-1 und Antithrombin III inhibiert. Wenn die 
FSAP in Komplexen mit PN-1 oder PAI-1 vorlag, konnte ihre Internalisierung durch 
einen LRP abhängigen Mechanismus, in glatten Muskelzellen und Fibroblasten, 
aufzeigen werden. Demzufolge ist LDL Receptor-releated protein (LRP) für die 
Beseitigung der FSAP-Inhibitor Komplexe verantwortlich. Die Funktionalität des LRP 
ist wichtig für die Regulation des PDGF-BB Signalweges. Die Interaktion der FSAP-
Inhibitor Komplexe mit LRP hatte jedoch keinen Einfluss auf die LRP abhängige 
Regulation der PDGF-BB Signalübertragung. 
Der inhibitorische Effekt der FSAP auf die PDGF-BB abhängige 
Zellaktivierung wird durch eine spezifische Spaltung des PDGF-BB Moleküls erzielt. 
Die Spaltstellen der FSAP im PDGF-BB Molekül wurden identifiziert. Damit wurde 
aufgezeigt, dass durch die FSAP abhängige Spaltung das rezeptorbindende Motiv des 
PDGF-BB zerstört wird. Demzufolge ist die verringerte proteolytische Aktivität der 
MI-FSAP der bestimmende Faktor für ihre Verbindung zu vaskulären Krankheiten, 
welches durch ihre Unfähigkeit zur Inhibition der PDGF-BB abhängigen Aktivierung 
glatter Muskelzellen aufgezeigt wurde. 
Mit den in dieser Arbeit präsentieren Resultaten wurden neue Einsichten in die 
komplexen Mechanismen, welche an der Regulation der FSAP beteiligt sind, 
geschaffen. Ein besseres Verständnis dieser Mechanismen könnte zu neuen 
therapeutischen Ansätzen zur Behandlung von fibro-proliferativen, krebs-assoziierten 
und arteriosklerotischen Krankheiten führen. 
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